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Introduction
INTRODUCTION
Independence: a global problem
Around the world it is commonly assumed that 
clinical practice guidelines, systematic reviews 
and the scientific literature are dependable and 
credible sources of information about the efficacy 
and effectiveness of therapeutic products. Health 
practitioners and consumers expect that these are 
reliable sources of up-to-date information about 
treatment options, and policy makers rely on them 
to guide important healthcare decisions. Yet all these 
publications are subject to many influences that can 
threaten their independence1, including:
 • the suitability of clinical research funding
 • the limitations of conventional clinical trials
 • the reliability of the evidence base
 • the competing interests of guideline developers 
and other experts involved in guideline 
development.
Suitability of clinical research funding
Being situated in the private sector, the 
pharmaceutical industry is driven by commercial 
principles. It responds to incentives to develop 
new drugs, which are often more expensive than 
established therapies. Because of its size and financial 
power, the industry has a major influence on the 
nature of the research agenda. Companies decide 
which questions will be researched and then they 
design and fund trials to ensure their new drugs 
are seen in the best possible light. As a result, the 
pharmaceutical industry is exerting considerable 
influence over the development of clinical practice.
In recent years, there has been a trend in the industry 
to modify society’s perception of disease. It actively 
campaigns for expanded definitions of diseases, 
which often results in normal processes being labelled 
as pathological ones. Despite limited evidence, this 
is happening in many areas, notably for menopause, 
blood glucose, blood cholesterol and other lipids, 
blood pressure and bone density. By expanding 
indications for treatment, the prescribing rate for 
the newest drugs increases, as does the likelihood of 
adverse effects.
Appropriate treatment often involves non-drug 
therapies or the use of more established drugs. 
Because there are very few sources of funding for 
research on either non-drug therapies or therapies 
that are unlikely to produce an economic benefit 
This supplement is likely to be of interest to anyone 
involved in the development of clinical guidelines and 
clinical research, including:
 • health professionals, trainees and students who 
use guidelines as a basis for their decision making
 • policy makers and others working to improve the 
quality of health care
 • people involved in university, college and hospital 
education. 
The supplement outlines the issues discussed at 
an Independence Forum hosted by Therapeutic 
Guidelines Limited in Melbourne, Australia, on  
29 October 2012. It puts forward recommendations 
to overcome limitations of the evidence base and 
improve the trustworthiness of guidelines.
Therapeutic Guidelines is an independent, not-for-
profit organisation that was established to promote 
the quality use of medicines through the publication 
of clear, concise and ready to use guidelines. 
Therapeutic Guidelines convened the Independence 
Forum to discuss issues of independence and  
conflicts of interest in the context of the  
development of therapeutic guidelines for  
health professionals.
Two eminent overseas speakers, Professor Silvio 
Garattini from the Mario Negri Institute, Italy, 
and Assistant Professor Barbara Mintzes from 
the University of British Columbia, Canada, gave 
keynote presentations on the complexity of the 
therapeutic environment and clinical evidence base. 
Key Australian commentators and health ethicists – 
Professor Paul Komesaroff from the Centre for the 
Study of Ethics in Medicine and Society at Monash 
University, and Associate Professor Ian Kerridge 
from the Centre for Values, Ethics and the Law in 
Medicine at the University of Sydney – focused on 
the influence of vested interests in clinical research 
trials and guideline development, citing high profile 
examples such as the case of hormone therapy after 
menopause. Panel discussions provided insights on 
these issues from a range of perspectives, including 
government, evidence-based medicine, clinical 
research, health professionals and community. During 
the last session, speakers and participants worked 
in small groups to formulate recommendations 
and strategies to improve the suitability of the 
evidence base and trustworthiness of therapeutic 
recommendations and guidelines.
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INTRODUCTION
for pharmaceutical companies, the evidence base is 
becoming increasingly biased towards the use of new 
drug therapies.
Limitations of clinical trials and 
reliability of the evidence base
Flaws in the design of randomised controlled trials can 
magnify benefits and obscure the adverse reactions 
of a drug. Common deficiencies and biases identified 
in the literature include:
 • abuse of placebo – new drugs tend to be 
compared with placebo rather than an established 
comparator, which would discern whether the new 
drug offers an advantage over standard treatment
 • non-inferiority trials – such trials are designed to 
show a drug is not worse than standard therapy. 
There is usually no requirement to demonstrate 
the superiority of a new drug.
 • selection of a comparator – ideally a new drug 
should be tested against the best standard, at 
the best dose and duration of treatment. There 
is no requirement to assess the drug's safety and 
effectiveness against the current gold standard 
treatment.
 • surrogate endpoints – it is common for the 
efficacy of a drug to be measured using an 
indicator that may (or may not) reflect an 
advantage, rather than measuring a clinical effect 
relevant to the patient
 • composite endpoints – the trend for different 
endpoints to be grouped and analysed together 
makes it difficult to determine clinical significance
 • exclusion of relevant populations – new drugs 
are frequently tested on men rather than the 
population that will be using the drug (e.g. women, 
older people, children, people with comorbid 
conditions). Consequently, there is often little or 
no information about which groups of people do 
better or worse with treatment, and little research 
on the impact of drugs on patients’ function and 
lived experiences.
Analysis of trial data shows a direct link between 
the funding source and outcomes of a study, with 
industry-sponsored trials being approximately two-
and-a-half times more likely to favour a drug than 
publicly funded trials.
Publication bias is another important barrier 
to independence. Positive results that show an 
intervention works are more likely to be published 
than negative results. Trials that fail to show benefit 
may never be published and seem to be under-
represented in the published literature. In some cases 
trial results are published selectively, with positive 
results prioritised, rather than the full set of measured 
outcomes. These systematic biases are a challenge 
for all those engaged in health, and in particular 
to groups producing evidence-based guidelines, 
evidence reviews and health policy.
Conflicts of interest
In recent years questions have been raised in the 
international therapeutic community about both 
the reliability of clinical drug trial data and the 
management of real or perceived conflicts of interest 
in guideline development groups. An editorial in the 
British Medical Journal, for example, indicates that the 
pharmaceutical industry has repeatedly withheld and 
misreported data on the safety and efficacy of a range 
of widely used drugs, limiting treatment benefits, 
endangering lives and wasting public money.2
Scientific data are always interpreted in the context 
of existing societal views and influences. People 
relying on trial results as a basis for developing 
guidelines need to be aware of the spectrum of 
influences that can bias the collection, analysis 
and interpretation of data. Conflicts of interest can 
occur when a commitment, goal or value that arises 
from a professional or social role is perceived to 
unduly influence the independence of data or their 
interpretation. Such conflicts include:
 • pecuniary interests
 • academic or professional interests that might 
accrue from publications, awards, media, 
professional attention or kudos
 • personal or religious beliefs, or experience of a 
health-related condition (either personally or a 
close family member or friend affected).
International concern
Guideline developers around the world understand 
the need to create reliable and trustworthy guidelines 
according to the highest standards and they 
are becoming increasingly mindful of threats to 
independence.
Tools have been developed to appraise guidelines and 
to establish whether the views of the funding body 
have influenced the content of guidelines and whether 
the competing interests of guideline development 
group members have been appropriately managed.3
In the USA, the Institute of Medicine published a 
report outlining concerns about the quality of the 
processes used to develop clinical practice guidelines, 
the limitations in the scientific evidence base on 
which clinical practice guidelines rely, the lack of 
transparency in development groups’ methodologies, 
and the management of conflicts of interest among 
guideline development group members and funders.1
7www.australianprescriber.com
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In 2012 the Guidelines International Network published 
recommendations for minimum standards for quality 
guidelines4 and in the same year the National Health 
and Medical Research Council published a report on 
managing conflicts of interest in the development of 
guidelines.
Despite the introduction of standards promoting 
conflict of interest policies, a growing number of 
reviews of clinical practice guidelines conducted in 
the last 10 years have revealed that the majority of 
guideline developers do not in fact publicly disclose 
any of their authors’ conflicts of interest. In 2009 the 
Medical Journal of Australia published a review5 that 
analysed 313 Australian clinical practice guidelines. 
The review found that almost 80% of the guidelines 
analysed included no information on the conflicts of 
interest of the members of their development groups. 
Similar findings have been published in relation to US 
and European guidelines.
The Independence Forum
The central aim of Therapeutic Guidelines is to 
promote the quality use of medicines through 
the development, publication and distribution of 
independent therapeutic guidelines. Independence is 
a critical issue for Therapeutic Guidelines so a number 
of strategies and policies have been implemented 
throughout the organisation and its operations 
to ensure the independence of the guidelines it 
develops.
The Independence Forum brought together  
national and international experts, ethicists,  
guideline developers, health professionals, clinical  
researchers and medical writers to identify threats to  
independence and discuss measures that could be  
taken to identify and counteract them.
INTRODUCTION
1. Institute of Medicine (US). Committee on Standards for 
Developing Trustworthy Clinical Practice Guidelines. Clinical 
practice guidelines we can trust. Washington, DC: National 
Academies Press; 2011. 
2. Godlee F. Clinical trial data for all drugs in current use.  
BMJ 2012;345:e7304. 
3. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F,  
Feder G, et al. Development of the AGREE II, part 1: 
performance, usefulness and areas for improvement.  
CMAJ 2010;182:1045-52. 
4. Qaseem A, Forland F, Macbeth F, Ollenschlager G, Phillips S, 
van der Wees P. Guidelines-International-Network: toward 
international standards for clinical practice guidelines.  
Ann Intern Med 2012;156:525-31. 
5. Buchan HA, Currie KC, Lourey EJ, Duggan GR. Australian 
clinical practice guidelines – a national study. Med J Aust 
2010;192:490-4.
REFERENCES
Speakers group: Professor Silvio Garattini, Associate Professor Barbara Mintzes, Associate Professor Ian Kerridge,  
Mr Richard Kneebone, Dr Sue Phillips, Professor Paul Komesaroff, Ms Mary Hemming
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PROGRAM
Program 
Monday 29 October 2012 
Melbourne
Time Topic Speaker/Moderator
0900–0910 Welcome Mr Richard Kneebone 
Chairman, Board of Directors 
Therapeutic Guidelines Limited
0910–0930 Setting the scene: 
Rationale for the forum and its aims
Dr Sue Phillips 
Chief Executive Officer, Therapeutic Guidelines Limited
0930–1010 Therapeutic independence: 
An international view of a global 
problem
Professor Silvio Garattini 
Director, Mario Negri Institute for Pharmacological 
Research, Milan, Italy
1010–1030 Moderated discussion Professor Paul Komesaroff 
Director of the Monash Centre for the Study of Ethics in 
Medicine and Society, Melbourne
1030–1100 Morning tea
1100–1130 Evidence-based medicine: 
Strengths and limitations
Assistant Professor Barbara Mintzes 
School of Population and Public Health, University of 
British Columbia, Vancouver, Canada
1130–1230 Discussion by panel of experts 
selected to represent a range of 
viewpoints
Professor Paul Komesaroff
1230–1330 Lunch
1330–1350 Cautionary tales about how we 
make decisions: Balancing truth, 
facts, values and interests
Professor Paul Komesaroff
1350–1410 Experts, guideline development and 
competing interests
Associate Professor Ian Kerridge 
Centre for Values, Ethics and Law in Medicine,  
University of Sydney
1410–1500 Discussion by panel of experts 
selected to represent a range of 
viewpoints
Professor Paul Komesaroff
1500–1530 Afternoon tea
1530–1615 Informal small group discussions to 
develop draft recommendations
Professor Paul Komesaroff
1615–1655 Moderated discussion of proposed 
recommendations
Professor Paul Komesaroff
1655–1700 Thank you and farewell Mr Richard Kneebone
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Rationale for the Forum
Reliable research is an integral component of 
Therapeutic Guidelines. To ensure that the evidence is 
appropriately assessed, Therapeutic Guidelines works 
with people who have both critical appraisal skills and 
the relevant clinical experience to provide guidance 
about the treatments most likely to be beneficial and 
least likely to cause harm to patients.
The issue of conflict of interest has been the focus of 
much discussion in the guideline community and in 
other contexts and a number of organisations have 
developed conflict of interest policies as a result. For 
example, to develop the American Thoracic Society’s 
Official Policy Statement on the management of 
conflicts of interest1, Schünemann and colleagues 
used existing reviews of policies that were prepared 
for the World Health Organization (WHO) and for an 
American Thoracic Society guideline methodology 
workshop as their evidence base. They also looked 
at the policies of selected organisations (American 
College of Physicians, American College of Chest 
Physicians, American Medical Association, Society 
of Critical Care Medicine, International Committee 
of Medical Journal Editors, and WHO). The resulting 
American Thoracic Society Policy Statement provides 
the following, particularly helpful definition:
Conflict of interest is defined as a divergence 
between an individual’s private interests and 
his/her professional obligations such that 
an independent observer might reasonably 
question whether the individual’s professional 
actions or decisions are motivated by personal 
gain, such as financial, academic advancement, 
clinical revenue streams, or community 
standing.
So, how well is conflict of interest managed in clinical 
practice guidelines? Research over the last 10 years 
shows that many guidelines do not disclose author 
conflict of interest statements:
 • 79% in a study of 313 Australian guidelines (2009)
 • 58% in 215 guidelines involving drugs on the 
National Guideline Clearinghouse (2004)
 • 95% in 44 guidelines endorsed by North American 
and European societies (2002).
However, the landscape is gradually changing. The 
need to declare and publish conflicts of interest is 
now more widely accepted, and current thinking is 
that robust mechanisms are needed to help manage 
people’s declared conflicts. Many organisations have 
Therapeutic Guidelines Limited is a not-for-profit 
company. Its reputation is staked not only on 
its publications, but also on its independence of 
government and pharmaceutical interests. It is 
financially self-sufficient and does not receive any 
form of government or industry funding. This is a very 
satisfactory position to be in, both intellectually and 
administratively, but it also means that Therapeutic 
Guidelines needs to carefully manage its resources, 
relationships with other organisations and the clinical 
community, and the decisions it makes about the use 
of its products.
Therapeutic Guidelines evolved out of activities 
dating back to the 1970s, when a group of health 
professionals formed to develop antibiotic guidelines 
in response to the worrying and emerging problem of 
antibiotic resistance. The guidelines are now widely 
respected and are an accepted part of the Australian 
medical culture. They are characterised by their 
comprehensiveness, authority, convenience, currency 
and reputation for being a trustworthy source of 
independent therapeutic advice.
The Therapeutic Guidelines collection currently 
includes around 3000 topics, which are 
regularly revised and published. Experts work in 
multidisciplinary groups to consider feedback, assess 
and evaluate the evidence and develop the content. 
The finalised content is reviewed by external experts  
if required, endorsed by professional organisations 
and vetted through internal quality control  
processes.
The Therapeutic Guidelines website (www.tg.org.au)  
provides detailed information about the history 
and activities of Therapeutic Guidelines, including 
a description of the process used to develop the 
content, and our activities to support the quality use 
of medicines in developing countries.
Preparing guidelines is a complex process involving 
a large number of players. There are several areas 
where independence and bias need to be considered, 
and several factors that can threaten the reliability 
of the advice Therapeutic Guidelines provides. Every 
step needs careful thought and planning to maintain 
the integrity of the process. In some areas, such as 
managing conflict of interest, Therapeutic Guidelines 
can institute measures that allow it to control the 
integrity of the process. In other areas, such as the 
limitations of the available evidence, Therapeutic 
Guidelines has much less control.
Dr Sue Phillips
Chief Executive Officer 
Therapeutic Guidelines 
Limited 
Melbourne
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Therapeutic Guidelines Limited’s 
conflict of interest policy
The pharmaceutical industry and government both 
rely heavily on bodies outside their own spheres, such 
as universities and hospitals, for product development 
and regulation. In this context, given their experience 
and expertise, it is likely that Therapeutic Guidelines 
directors and members of expert groups have, or 
have had, some association with the pharmaceutical 
industry and government committees.
To minimise the possibility of inappropriate influences, 
Therapeutic Guidelines has included the following 
strategies in its conflict of interest policy:
 • Expert group members are asked to declare 
any potential conflicts of interest before being 
appointed.
 • Once appointed, a register of declared interests 
is maintained, circulated and updated at every 
expert group meeting.
 • All expert group meetings are chaired by 
Therapeutic Guidelines’ Medical Advisor, who 
has no conflicts of interest that could, or could be 
perceived to, erode the integrity of the guidelines.
 • The Chair decides how to manage declared 
interests and discusses these with expert group 
members.
 • Information about expert group members’ 
declarations of interest and how these were 
managed are published when the guidelines are 
released.
The conflict of interest policy for the Board of 
Therapeutic Guidelines and all members of its 
guideline teams is available on the website. This new 
policy was updated in 2012 to ensure that declared 
conflicts of interest are also published online. It is 
being implemented prospectively as each guideline is 
updated and new expert groups are established and 
provide their consent.
To conclude, one of the key objectives for this 
forum is to consider best practice regarding the 
management of conflicts of interest and to identify 
whether there is anything further that Therapeutic 
Guidelines should do to manage potential sources of 
bias when developing its guidelines.
Equally important is the need to focus on the issue 
of bias in the research literature and evidence base, 
and to consider whether new sources of funding and 
regulatory changes are needed to improve the scope 
and design of clinical trials.
1. Schunemann HJ, Osborne M, Moss J, Manthous C, Wagner G, 
Sicilian L, et al. An official American Thoracic Society Policy 
statement: managing conflict of interest in professional 
societies. Am J Respir Crit Care Med 2009;180:564-80.  
2. Institute of Medicine (US). Committee on Standards for 
Developing Trustworthy Clinical Practice Guidelines. Clinical 
practice guidelines we can trust. Washington, DC: National 
Academies Press; 2011.
3. Qaseem A, Forland F, Macbeth F, Ollenschlager G, Phillips S, 
van der Wees P. Guidelines International Network: toward 
international standards for clinical practice guidelines.  
Ann Intern Med 2012;156:525-31.
REFERENCESpublished advice in this area, but the US Institute of 
Medicine2 and the Guidelines International Network3 
statements are particularly useful.
In 2008, the Institute of Medicine was directed 
by the US Congress to develop standards for the 
development of rigorous, trustworthy clinical practice 
guidelines. This was prompted by concerns from 
clinicians, methodologists and consumer groups 
about the quality of guideline development processes 
and the resulting questionable validity of guideline 
recommendations and guideline-based performance 
measures. Three years later, the Institute published 
a 266 page report that contained eight proposed 
standards covering all the elements considered to be 
essential to developing sound guidelines.2
The Institute of Medicine report proposes the 
following strategies for managing conflicts of interest:
1. Written disclosure of current and planned,  
commercial and noncommercial, intellectual,  
institutional, and patient–public activities  
pertinent to the scope of the guidelines before  
appointment.
2. Each expert group member to report and 
discuss all conflicts of interest with the group 
and explain how their conflict of interest could 
influence the development process or specific 
recommendations before starting the work.
3. Members to divest themselves of financial 
interests they or their family members have, and 
not participate in marketing activities or advisory 
boards of entities whose interests could be 
affected by the recommendations.
4. Whenever possible, expert group members should 
not have conflicts of interest.
5. In circumstances where expert groups are not 
able to perform their work without members who 
have conflicts of interest, such members should 
represent not more than a minority of the expert 
group.
6. The Chair or Co-Chairs should not have conflicts of 
interest.
7. Funders should have no role in the development 
process.
In response to concerns about the feasibility of 
implementing such a long list of criteria, Guidelines 
International Network developed a more succinct 
seven page document that proposes a minimum set 
of international standards for developing trustworthy 
guidelines.3
Both sets of standards emphasise the need for 
strategies to actively and transparently manage 
conflicts of interest.
11www.australianprescriber.com
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Therapeutic independence:  
A global problem
the national health service is, in general, relatively 
scarce. This creates an asymmetric system driven by 
economic interests, while the national heath service 
has limited influence.
The imbalance between the industry-funded 
information and independent information has led to 
distortion in the conception of medicinal products, 
which are becoming consumer goods rather than 
therapeutic tools.
How drugs satisfy patients’ needs
Each year the US Food and Drug Administration 
authorises about 60 new chemical entities to be 
marketed, and the European Medicines Agency 
authorises about 30 new entities. The importance 
of these new products is very limited since they are 
often drugs belonging to an existing therapeutic 
class, with only small chemical changes. In addition, 
in the last decade there has been an increase of 
biopharmaceuticals (obtained by DNA-recombinant 
techniques, such as monoclonal antibodies).
The analyses to date indicate that most new medicinal 
products are not necessary. One French study showed 
that out of 961 drugs approved in the period  
1999–2008 about 49% brought nothing new, 11% were 
‘not acceptable’, and the others could offer some 
benefits, but only 2% provided any real advantage.1 
Another study analysed the improvements in quality 
of life, expressed as quality-adjusted life years 
(QALY), induced by 281 new medicinal products. Only 
12% induced more than 1 QALY, while 51% induced less 
than 0.1 QALY.2
Some confusion arises depending on the parameters 
used to establish the progressive value of therapy. 
A percentage can be misleading, and it is better to 
express the advantage in absolute terms. A clear  
idea about the value of a drug can be estimated from 
the number of patients that must be treated with a 
given drug in order to obtain a positive outcome in 
terms of reduced mortality or morbidity – the  
number needed to treat (NNT). The same can be 
done using the number needed to harm (NNH), 
i.e. the number of patients that must be treated to 
observe an important adverse event. The ratio of 
NNT to NNH constitutes an attempt to identify a 
‘therapeutic ratio’.
A fair evaluation of medicinal products should not 
only be quantitative, but should also address the 
The complexity of the therapeutic 
environment
The authorisation and the life of a drug are dictated 
by a number of stakeholders. If it is possible to list (in 
decreasing order of importance) the responsibility to 
provide a drug to a patient, it might be as follows:
 • Legislative bodies – the law determines the 
general framework of the pharmaceutical 
environment. The European Medicines Agency is 
responsible for the regulation and approval of  
new drugs in Europe, and publishes three 
documents:
 – the leaflet for patients
 – the Summary of Product Characteristics for 
physicians
 – the European Public Assessment Report 
describing the pathway that led to approval. 
National agencies usually have only a minor role in 
the approval of drugs (today mostly generics) but 
are very important for reimbursement by national 
health services.
 • Scientific societies – these are generally 
responsible for drafting guidelines and in some 
cases must exert pressure to obtain rapid approval 
of drugs (e.g. for anticancer drugs)
 • Prescribers – whether in hospitals or primary care, 
prescribers have the final decision of what to give 
the patient
 • Patients or consumer associations – these groups 
usually have very limited influence.
All these stakeholders are influenced by two forces: 
 • the pharmaceutical industry, which is obviously 
interested in selling as many medicinal products as 
possible at the highest possible price
 • the national heath service, which funds the 
provision of only essential drugs to patients at the 
lowest possible price.
Pharmaceutical companies, either directly or through 
their lobby groups (e.g. the European Federation 
of Pharmaceutical Industries and Associations in 
Europe), have the ability to influence all stakeholders. 
Their support of scientific societies, marketing to 
prescribers and the financing of patients’ associations, 
as well as the media, is pervasive and extremely 
effective. In contrast, information coming from 
Professor Silvio Garattini
Director  
Mario Negri Institute for 
Pharmacological Research 
Milan, Italy
THERAPEUTIC 
INDEPENDENCE
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 • the combination of metformin with a new 
antidiabetic drug where placebo is used, despite 
established standard treatment combinations of 
two antidiabetic drugs
 • the comparison of antidepressants where placebo 
is not necessary if the trial is designed to detect 
superiority.
Comparator
Selection of the comparator is very important 
because it can affect the evaluation of the new 
drug. Ideally the best standard should be used, at 
the best dose and duration of treatment. In practice 
these variables are often selected in order to favour 
the new drug. For instance in the case of rofecoxib, 
comparison with naproxen would have detected the 
cardiovascular adverse effects induced by rofecoxib. 
In another example, tacrolimus was shown to be 
superior to cyclosporin only because cyclosporin was 
used at suboptimal doses.
Non-inferiority trials
In this type of trial, investigators test the null 
hypothesis that a new drug is worse than the active 
control (standard therapy). When they can reject the 
null hypothesis, they accept the alternative, the new 
drug is not worse, but do we really need non-inferior 
drugs? Often the difference for acceptance of non-
inferiority may be 25–50%. Patients rarely receive 
clear information in the informed consent form about 
the significance of this experimental design.
Surrogate end points 
Frequently the evaluation of a drug is not based 
on therapeutic advantages for the patients, but 
on indicators that may indirectly reflect possible 
advantages. Examples are decreased blood 
cholesterol as a surrogate for reduction of myocardial 
infarction, decreased blood pressure as a surrogate 
for reduction of stroke, and decreased blood glucose 
as a surrogate for cardiovascular complications 
of diabetes. In some cases therapeutic end points 
are considered equivalent to surrogate end points, 
particularly when a group of drugs belong to a class 
with a similar mechanism of action.
However, since each drug has its own chemical 
structure, adverse reactions may in fact outweigh 
the benefit. Statins are an example. Rosuvastatin 
was approved for use on the basis of its 
hypocholesterolaemic effect, but simvastatin and 
pravastatin had already demonstrated protective 
effects against myocardial infarction. Cerivastatin was 
withdrawn because of toxicity. In another example, 
several anticancer drugs have been approved on the 
grounds that they reduce tumour volume, but with no 
relation between patients’ unmet needs and efforts 
to make drugs available to meet these needs. For 
instance, bacterial resistance to antibiotics has not 
been followed by the development of new antibiotics 
effective against resistant microorganisms. Similarly, 
there have been no truly new agents for mental 
disorders (psychotropic drugs) in the past 30 years, 
and several important multinational pharmaceutical 
companies have abandoned this field of research.
A recent study pointed out the discrepancy between 
the burden of a given disease and the number of 
drugs available. Epidemiological data indicate that 
while there has been a considerable decline in 
mortality due to cardiovascular diseases, in the field 
of cancer (namely breast and colorectal cancers) in 
the last decade there has been less improvement 
over previous decades despite the number of drugs 
approved.
Orphan drugs merit special mention. In the last 10 
years only 63 drugs have been approved by the 
European Medicines Agency for the 6000 rare 
diseases awaiting treatment. In some cases the 
evidence of a favourable benefit–risk ratio is very 
doubtful. Similar considerations are offered for the 
lack of new drugs for the neglected diseases of 
people in developing countries.
Bias in randomised controlled  
clinical trials 
The scientific literature has recognised a number of 
biases that affect randomised controlled trials. In 
general these tend to magnify the benefit of a drug 
and minimise adverse reactions. All these biases lead 
to poor innovation.
Abuse of placebo 
It is obvious that a comparison with placebo rather 
than with an active comparator allows better 
appraisal of a drug’s benefit. In this respect there is 
considerable disagreement between the Declaration 
of Helsinki and the rules issued by the US and 
European regulatory agencies. There are three 
different types of abuse of placebo: 
 • direct comparison with placebo (two-arm studies) 
 • use of placebo in an add-on design
 • the three-arm design (placebo, comparator,  
new drug). 
In all three cases not using the comparator (when 
available) can harm patients in the placebo group 
because they receive no treatment or treatment that 
is less than optimal. Examples of this bias include: 
 • the recent direct comparison of placebo with 
drugs developed for multiple sclerosis (e.g. 
cladribine, fingolimod, laquinimod)
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Adequate postmarketing follow-up is therefore 
important. However, most drug withdrawals are 
instigated by  pharmaceutical companies rather than 
the regulatory authority, indicating that appropriate 
follow-up by regulatory authorities does not occur. In 
addition, withdrawal is often considerably delayed, 
such as in the case of rofecoxib, cerivastatin, 
rosiglitazone, sibutramine, and rimonabant.
Some proposals for change
It is difficult to change the present system because 
all stakeholders have some vested interests. However, 
the present crisis may offer an opportunity to make 
some changes.
There are essentially three changes needed to the 
legislation:
 • The approval of a new drug presently requires only 
evidence of quality, efficacy and safety. It would 
be important to also require ‘added value’. This 
would abolish pivotal studies of non-inferiority 
and would require comparative studies in order to 
identify advantages over drugs already available 
on the market.
 • Confidentiality should be abolished, at least for 
pharmacological, toxicological and clinical data. 
There is no reason to maintain confidentiality 
because, for clinical trials in particular, the data 
belong to the patients. Without their generosity 
there would be no clinical trials.
 • The regulatory authorities should be funded 
from public sources. The European Union and its 
member states could recover their funding from 
industry in different ways.
These changes in legislation would result in stricter 
approval processes that allow only drugs that offer 
true innovation in therapeutic terms to be marketed 
(see Table).
To avoid bias in trials, one of the two pivotal  
phase III trials should be carried out by an 
independent non-profit organisation.
evidence of improvement in overall survival or quality 
of life.
Composite end points 
Where specific events are relatively few, it has 
become customary to group several events together. 
For instance death, myocardial infarction, stroke 
and coronary artery occlusion may be grouped 
as ‘cardiovascular events’. When a drug achieves 
a statistically significant decrease in a composite 
end point it is proclaimed that all the individual end 
points have been beneficially affected. However, the 
significance is usually driven by minor points that are 
less important therapeutically.
Fragile populations
New drugs are frequently tested on men rather 
than the population that will be using the drug, such 
as older people. Children are rarely recruited for 
trials, nor are women of fertile age. Furthermore, 
patients are selected for trials in artificial conditions, 
while in clinical practice patients may have multiple 
comorbidities and be taking several drugs already. 
Consequently, the trials may overestimate the drug’s 
benefits and underestimate its harms in clinical 
practice.
Publication bias
This term refers to the tendency to favour publications 
showing positive results rather than negative ones. 
This has created a number of problems in drug 
assessment. For instance, the selective serotonin 
reuptake inhibitors have been considered active in 
mild depression even though they are not different 
from placebo. Reboxetine is overall an ineffective and 
potentially harmful antidepressant when positive and 
negative trials are assessed together.3 The suicidal 
tendencies induced by antidepressant drugs in 
adolescents have not been well publicised.
Adverse reactions
The risk induced by drugs can seldom be detected 
during trials because they recruit too few people. 
Table    Regulatory evaluation of clinical trials
Current Ideal
Kind of comparison None
Superiority to placebo
Non-inferiority to active comparator
Superiority to the best available care
Kind of comparator (and its dosage) Not always the most appropriate The best available treatment
Outcome measure Surrogate outcomes Clinically meaningful outcomes addressing significant 
better and/or longer life
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undertake a systematic review or a meta-analysis of 
trials that have already been done. Unfortunately, a 
number of trials are still done without any preliminary 
review. These studies waste resources and expose 
people to undue risks. In Europe a six-month patent 
extension is offered as an incentive to carry out trials 
in children. In some cases it would be less expensive 
for the national health service to fund these trials, 
providing the results are recognised by the regulatory 
authority.
The present legislation for randomised controlled 
trials (through Good Clinical Practices) does not 
distinguish between the requirements necessary for 
a new medicinal product and those for independent 
research using drugs already on the market (e.g. 
for comparison, optimisation or new indications). 
These studies should be less burdened by official 
requirements. The risk of a given trial should dictate 
the need for insurance, the grading of monitoring and 
the reporting of adverse reactions.
In Europe the European Clinical Research 
Infrastructure Network has been created to assist 
international trials by providing the necessary 
information and helping to deal with national 
differences in clinical trials requirements.
Discussion
Following Professor Garattini’s presentation, 
participants raised the following key points in 
discussion:
 • The concept of introducing a 5% levy on drug 
companies to fund investigator-initiated research 
was seen as a good idea. This money could also be 
used to fund research that would provide reliable 
information about the effectiveness of drugs in 
those high-need population groups that are likely 
to benefit from the drugs (e.g. children, women, 
the elderly).
 • Guideline developers must constantly assess 
whether the study design of a trial is applicable to 
their target populations.
 • There is a lack of trials evaluating non-drug 
interventions, such as physical activity or dietary 
changes, which may be just as effective as drug 
therapy for managing disease and improving 
health outcomes.
 • A number of complementary and alternative 
therapies are actively advertised and promoted 
as having a therapeutic benefit. While not all of 
these therapies may be dangerous, there is no 
requirement to demonstrate their efficacy in 
rigorous trials, so there are no data about their 
effectiveness. There should be consideration of 
introducing the same regulatory framework for 
Regarding adverse reactions, it is important to 
require ‘active pharmacovigilance’. At present the 
Committee for Human Medicinal Products, a technical 
advisory body of the European Medicines Agency, 
is responsible for the approval (or rejection), appeal 
and withdrawal of drugs. This creates a conflict of 
interest, since it is hard for the same body to exert 
contradictory functions. A separate committee should 
be responsible for monitoring for adverse effects 
over the life of a drug and making decisions about 
modifying the summary of product characteristics or 
withdrawing a drug.
Independent research must be promoted at the 
preclinical and clinical levels. There is a tendency to 
translate the effects of a drug too fast from laboratory 
to humans. Although this can be done on healthy 
volunteers under specific conditions, thorough 
evaluation is essential in vitro and in several animal 
species and models of human diseases. The action of 
antivivisection groups poses a serious obstacle to the 
extension of laboratory tests to animals. In addition, 
excessive bureaucratic rules hamper the development 
of knowledge useful to understand drug actions. It 
must be recognised that the pharmacological effect 
in animal tests is frequently too small to suggest real 
therapeutic action. The example of some anticancer 
drugs is pertinent in this respect.
Investigator-driven clinical trials organised by  
non-profit organisations should be encouraged 
by making available funding and infrastructures, 
particularly for international collaboration on large 
clinical trials, and trials for rare and neglected 
diseases. For the past two years, special topics 
for independent trials have been supported under 
Framework Program 7 in Europe. In Italy a special law 
has established a research fund by taxation of 5% on 
all promotional expenses (except salaries) borne by 
pharmaceutical companies.
For five years there have been annual calls for 
investigator-driven clinical trials comparing drugs for 
the same indications, addressing new indications for 
old drugs, or testing orphan drugs. An international 
peer review assigns funds to the selected proposals. 
The independent research is not only useful for better 
evaluation of drug toxicity and activity, but also to 
optimise doses and duration of treatment. In some 
cases equivalence of drugs with different prices can 
allow savings on drug expenses. Independent trials 
should also aim to involve practitioners in order to 
evaluate drugs in current clinical practice, particularly 
in the elderly and children.
In order to avoid repetitive studies and delay in 
developing new indications or contraindications, 
before starting any new trial it is important to 
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the approval of these products as there are for 
registered drugs.
 • Off-label use of products is hard to monitor and 
evaluate.
 • There is a need to engage more closely with the 
public and consumers to get input into the topics 
of greatest concern for them and incorporate this 
information into the research agenda.
Professor Garattini explained the Mario Negri Institute's 
policy on competing interests (see Appendix 2 for details)
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Evidence-based medicine:  
Strengths and limitations
The work of the Cochrane Collaboration and other 
evidence-based groups has grown significantly over 
the last 20 years. In 1981 there were only three meta-
analyses indexed on Medline, in 1986 only 26. By 2011 
the number had grown to around 8000.
Has the evidence-based movement been captured by 
commercial interests? Despite the rapid growth in the 
scale of activity to develop robust systematic review 
processes and procedures, there is a fundamental 
block in terms of limitations in the clinical trial 
evidence on the effects of new medicines. The 
requirements that manufacturers must meet to bring 
a new drug to market differ substantially from the 
clinical questions that physicians and patients face in 
order to understand a medicine’s place in therapy and 
decide whether or not to use it.
Studies of new pharmaceuticals are to a large degree 
shaped by regulatory requirements in order to obtain 
market approval. Currently, premarket randomised 
controlled trials are predominantly placebo controlled 
– or if not, they are non-inferiority trials. The latter 
are studies that are designed to test whether the 
drug is no worse than an existing treatment within 
a prespecified margin. Postmarketing surveillance 
data are mainly derived from observational studies. 
Regulators are becoming more interested in 
postmarketing safety surveillance, but there are no set 
standards for the rigour of the design of such studies.
Because most drug trials are designed and sponsored 
by the manufacturer, they are designed to present 
the drug in the best possible light and publication of 
all of the trial information is optional. When a drug 
becomes available there is usually no information on:
 • the effects in vulnerable population groups 
(because they will have been excluded from trials)
 • long-term or less frequent effects
 • clinical outcome efficacy (short-term surrogate 
outcomes are often used)
 • comparative effectiveness and safety.
There is no requirement for manufacturers to prove 
that their products are at least as safe as existing 
drugs. This has meant that some new drugs have 
turned out to have a worse safety profile than 
existing drugs. For example, the most frequent 
serious adverse event associated with use of 
combined oestrogen and progestogen-containing 
Evidence-based medicine is the conscientious, 
explicit, and judicious use of current best 
evidence in making decisions about the care of 
individual patients.1
David Sackett (1996)
This quote, from one of the gurus of evidence-based 
medicine, highlights the link between the systematic 
evaluation of scientific evidence on effects of medical 
treatments, and applying this evidence to patient care 
decisions – taking into account both clinical expertise 
and patient needs. Evidence-based medicine is not 
simply applying scientific evidence. It requires an 
assessment and interpretation in light of individuals’ 
health needs and preferences.
Although the first randomised controlled trials in 
medicine date from the 1950s, for many years there 
was no way to understand the body of information 
produced by drug trials and other forms of medical 
research. Writing in 1979, Archie Cochrane said:
It is surely a great criticism of our profession 
that we have not organised a critical summary, 
by specialty or subspecialty, adapted 
periodically, of all relevant randomised 
controlled trials.2
The Cochrane Collaboration (www.cochrane.org) was 
subsequently formed in 1992 and started its work 
looking at the effectiveness of obstetric interventions, 
as this was an area in which some interventions with 
substantial evidence of benefit were underused and 
others with little scientific basis remained widespread. 
The Cochrane Collaboration is an international 
network of more than 28 000 researchers from over 
100 countries with different review groups based 
on clinical specialties. It helps healthcare providers, 
policy-makers, patients and their advocates and 
carers make well-informed decisions about health 
care by preparing, updating, and promoting the 
accessibility of Cochrane systematic reviews. A 
strength is the focus on methodological rigour, 
and Cochrane reviews are often seen as the ‘gold 
standard’ in systematic review. Over 5000 reviews 
have been published online in the Cochrane Database 
of Systematic Reviews (part of The Cochrane Library). 
The Collaboration also prepares the largest collection 
of records of randomised controlled trials in the world, 
called CENTRAL (published as part of The Cochrane 
Library).
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oral contraceptives is venous thromboembolism. 
However, when a new oral contraceptive comes to 
market the manufacturer does not need to show that 
their newer pill has a lower or similar rate of venous 
thromboembolism to existing alternatives. Several 
newer oral contraceptives have been found to cause 
more venous thromboembolism than other oral 
contraceptives, including the drospirenone-containing 
products Yaz and Yasmin.3,4
In a regulatory environment without a requirement to 
establish an advantage in order to get a new drug to 
market, many new drugs are no more effective than 
existing alternatives. This overview is from La Revue 
Prescrire, a French independent drug bulletin that 
evaluates every new approved drug for its readership 
of over 30 000 practitioners.
The figure covers all new drugs and indications 
reviewed by La Revue Prescrire from 2002 to 2011.5 
Over half were judged to be ‘me too’ drugs – i.e. 
nothing new. Around 7% had solid evidence of an 
advantage over existing drugs (whether major or 
minor). In around 15% of new drug reviews there was 
evidence of poor effectiveness or safety compared to 
drugs already on the market.
Commercial influences and  
reporting bias
The pharmaceutical industry funds the majority of 
research, and therefore it also shapes the current 
research agenda. This leads to a bias of research focus 
on commercially viable interventions, where there is 
Judgement reserved,  
5%
Bravo, 0.2% A real advance, 1%
Not acceptable,  
15%
Offers an  
advantage,  
6%
Possibly helpful,  
21%
Nothing new, 52%
an anticipated beneficial outcome rather than harmful 
outcomes, and on products where there is likely to 
be a ready market. Consequently, there is not much 
research funding for drugs for neglected diseases 
affecting populations in low-income countries, where 
financial returns on research investments would be 
limited.
A body of research has examined the effects of 
industry funding on the evidence base and the types 
of bias it causes. A systematic review in the British 
Medical Journal in 20036 looked at the results of 
research trials in the US based on the type of funding 
the researchers received and the outcome of the trial 
data. It found that industry-funded trials are about 
four times more likely (95% confidence interval  
3.0–5.5) to favour the sponsor’s drug than non-
industry-funded trials. Another systematic review 
published in 2003 reported similar outcomes7, as  
have a number of more recent studies.
In late 2012, the first Cochrane systematic review on 
the effects of industry sponsorship was published, 
with a focus on studies of randomised controlled 
trials of drugs and devices.8 The authors found the 
same direction of effect as in previous systematic 
reviews but a lower magnitude: odds ratio = 2.2 
(95% confidence interval 1.7–2.7) for favourable 
results and odds ratio = 2.7 (95% confidence interval 
2.0–3.5) for conclusions as compared with non-
industry-sponsored studies. The difference likely 
reflects the focus only on trials rather than inclusion 
of a broader range of research designs, including 
pharmacoeconomic analyses. The authors failed to 
find any clear trend of improvement over time.
Industry funding has also been found to influence 
the reporting of active-controlled trials that compare 
drugs in the same class (head-to-head trials). A cross-
sectional study of head-to-head statin trials found a 
very strong association between the sponsor and the 
findings. Of 192 trials, 50% were sponsored by the 
test drug company, and these industry-funded trials 
were 20 times more likely to report results that favour 
the test drug over the competitor drug, and 35 times 
more likely to report favourable conclusions.9 Another 
study in 2010  looked at the outcome reporting 
among trials registered on the US Clinical Trials 
Registry covering six of the most heavily used classes 
of drugs (antidepressants, antipsychotics, proton 
pump inhibitors, lipid-lowering drugs, vasodilators). 
It found the proportion of favourable outcomes 
was high in trials funded both directly by industry 
and indirectly (i.e. trials conducted by non-profit 
organisations that receive industry funding).10
It is therefore clear from the literature that there is 
a direct link between funding source and outcomes 
Figure    Assessment of new drugs and indications by  
La Revue Prescrire 2002–2011 5
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The British Medical Journal has recently begun to 
provide a link to press releases on its website when 
it publishes a new article about a drug. A recent 
example of biased reporting in a press release was 
the 2012 reporting of the Heart and Estrogen/
Progestogen Study (HERS) on the effects of hormone 
replacement therapy (HRT) in women.13 The press 
release was titled ‘HRT taken for 10 years significantly 
reduces the risk of heart failure and heart attack’. 
This implies the findings contradict the Women's 
Health Initiative study, but important details were not 
mentioned: 
 • this was a post hoc secondary analysis of a trial 
that was developed to test HRT for osteoporosis 
and published 10 years earlier 
 • the post hoc analysis had an odd mix of primary 
outcomes (i.e. they included heart failure and 
heart attack as outcome measures even though 
heart failure was never considered to be a negative 
or positive effect of HRT)
 • the study was open label and used a questionable 
method of randomisation
 • the control group was on average a half year older 
and in poorer health.
Another area of potential bias that is sometimes 
difficult to detect is conflict of interest. A recent 
study looked at the disclosures of medical experts 
who had been named as illegally promoting off-label 
use of products in court cases in the USA.14 Ninety-
two people were named, 39 of them were authors 
of articles in the clinical area in which the off-label 
promotion occurred, and conflict of interest was 
adequately disclosed in only 15% of these articles.
Who and what is not being researched is another 
potential source of bias. When the COX-2 inhibitors 
(e.g. celecoxib, rofecoxib) were introduced they 
were marketed as being much safer than traditional 
non-steroidal anti-inflammatory drugs (NSAIDs) 
in terms of gastrointestinal bleeding. However, 
they had not been tested at all in people who 
were at high risk of bleeding (e.g. people who had 
previous gastrointestinal bleeds, the elderly). In an 
Ontario study of hospitalisations for the elderly for 
gastrointestinal bleeds, more bleeds occurred after 
these drugs began to be widely used, most likely 
because they were given to people who would not 
have otherwise been prescribed NSAIDs.15
Selective publication
Another source of bias in evidence-based medicine 
is the selective publication of research results. 
Erythropoietin and oseltamivir are two examples of 
publication bias leading to a distortion of the true 
therapeutic value of a drug.
of studies, and this leads to biased results. In a 
randomised controlled trial you would expect 
equipoise – you would not expect a situation where 
all trials funded by a specific source are two to three 
times more likely to be favourable than publicly 
funded trials.
Dissemination of information
The influence of the pharmaceutical industry extends 
beyond research. The other area where drug company 
influence is significant is the dissemination of 
information about the effectiveness of the drug and 
the trial results.
The pharmaceutical industry plays a dominant role 
in dissemination of information about drug products. 
It was estimated that US$57.5 billion was spent on 
drug promotion in the USA in 2004. This included the 
provision of samples, funding sales representatives, 
direct-to-consumer advertising, scientific meetings, 
promotions, advertisements and other unmonitored 
promotions.11 This is a massive investment – it would 
be great if 5% of this money went into a fund for 
independent research. It significantly outweighs the 
amount spent by public funders on the promotion 
and dissemination of health information, even in 
settings where there is a commitment to providing 
independent information. In the UK in 2005, the 
public sector spent only an estimated 0.3% of what 
industry spent on funding information dissemination, 
although the UK has more publicly provided health 
information than many other industrialised countries. 
Globally, Australia is one of the world leaders in 
having a larger commitment to publicly funded 
information.
This domination by industry poses a problem not only 
in terms of positively biased promotional information, 
but also the under-reporting of evidence about 
negative effects or harms.
There is also a lot of concern internationally about 
how the press represents or misrepresents research 
findings and how influential they are in creating public 
impressions of what drugs do or do not do. A review 
of press releases in EurekAlert (an online science 
news service) looked at the way journalists reported 
the results of a study and compared the reports with 
the study findings.12 It looked at different factors 
that were associated with ‘spin’ in the press release, 
i.e. misrepresentation of the study findings as more 
favourable and positive than they were. There was no 
association with the funding source of the study and 
the reporting of findings. Rather, the most significant 
factor was spin in the study itself (i.e. if the abstract 
represented the study findings as being more positive 
than the data would indicate).
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At the time Therapeutics Initiative did not realise 
how incomplete the evidence was, as this analysis 
was based on two published trials (one of which 
has subsequently been found to have been mainly 
ghostwritten). The US Food and Drug Administration 
approval of oseltamivir did not include publication 
on its website of the information submitted by the 
drug company until three years after the drug was 
approved for the market. For most drugs approved in 
the US, the Food and Drug Administration publishes 
a ‘review report’ on its website soon after approval, 
including a list of clinical trials submitted in the 
application, trial reports, and reviewer assessments.
The first Cochrane systematic review of oseltamivir 
in 2006 included a claim that it prevents flu 
complications.20 The review was based on one study 
report summarising the results of 10 pooled trials, 8 of 
which were unpublished, with most included patients 
in the unpublished trials.21 
One of the positive aspects of a Cochrane review 
is that authors are required to routinely update 
their reviews and must commit to responding 
to any comments posted about the review. A 
Japanese researcher queried the findings of the 
2006 pooled analysis of these 10 trials and asked 
whether the Cochrane reviewers had access to the 
full trial data for the 8 unpublished trials, and if not, 
how could the information supplied in the pooled 
analysis be trusted? As a result of this query, the 
Cochrane reviewers tried to obtain full reports of 
the unpublished trials. In the 2009 update of the 
Cochrane review, the claim that oseltamivir reduced 
flu complications was removed, as the data had 
not been disclosed. By 2012, when an updated 
Cochrane review was published, regulatory data 
had been disclosed. The authors found no effect 
on hospitalisation and could not pronounce on flu 
complications, due to incomplete and inconsistent 
reporting in the trials.
We found a high risk of publication and 
reporting biases … we are unable to draw 
conclusions about its effect on complications 
or transmission. We expect full clinical study 
reports ... to clarify outstanding issues. 
These full clinical study reports are currently 
unavailable to us.22
This experience demonstrates the discrepancy that 
can exist between published reports and the full 
reports of clinical trials submitted to regulators, and 
the importance of full disclosure. 
Erythropoietin is useful for people with very low 
haemoglobin. It stimulates red cell production and 
reduces the need for blood transfusions in people 
having cancer chemotherapy or kidney dialysis. 
Erythropoietin was in one of the 10 classes of 
medicines most heavily promoted to the US public 
in 200516, with strong messages that the drug 
would increase energy levels, improve quality of life 
and allow patients to live as normally as possible. 
Problems arose when the use of the drug was 
extended well beyond the areas where it was proven 
beneficial, and there has since been evidence of 
higher mortality in patients who did not have very 
low haemoglobin before starting erythropoietin 
therapy. Another problem is that erythropoietin has 
the ability to promote the growth of tumours, which is 
concerning if it is prescribed for people with existing 
cancers (one of the approved indications). There is 
a strong association between the funding source 
and basic science studies that did and did not find 
this potentially harmful effect.17 The major study that 
led to clinical guidelines recommending the use of 
erythropoietin for kidney dialysis patients has been 
republished 14 years after the original publication 
(after the full trial data were accessed through the 
Freedom of Information Act).18 It shows that the 
original authors omitted very important information 
about serious adverse effects and potential for harm, 
and overstated the benefits in terms of improved 
quality of life.
The international stockpiling of oseltamivir highlights 
the worldwide impact of biased reporting. Stockpiling 
has occurred on two occasions – first in 2006 with 
the threat of bird flu, and more recently with the 
H1N1 pandemic in 2009. Billions of dollars were spent 
by governments all around the world to purchase 
bulk supplies of oseltamivir, believing that it would 
prevent the transmission of the H1N1 virus and flu 
complications in their populations.
In a Therapeutics Initiative review published in 
2000, analysis of the clinical trial data showed that 
oseltamivir would only decrease the impact/duration 
of the flu by 0.7–0.8 of a day at best (about 18 hours) 
and that the effects on symptom severity were not 
able to be determined from the data. It found that the 
drug increased nausea and vomiting, and that there 
was no evidence that it prevented complications, 
hospitalisations or death. The trials excluded the 
elderly and chronically ill – the people who are at 
greatest risk from the virus.19
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 • enabling consumer groups to access data and 
have processes for involvement in all decisions
 • posting of regulatory review reports on the 
internet, after approval of all new drugs
 • development of alternate funding mechanisms 
for premarket trials so that these trials are not 
dominated by the pharmaceutical industry.
There is an important and stronger role for funders, 
payers and providers in research and resource 
allocation and managing the use of medicines 
through the provision of independent evidence-based 
information. One example of this is the approach 
taken by the non-profit health insurance plan, Kaiser 
Permanente, in the USA. They have developed an 
‘in-house’ research team to assess the effectiveness 
of resource allocation, including outcomes from 
spending on new drugs. The team also provides 
the organisation with its own physician and patient 
information services on health conditions and 
drug and non-drug treatments. Kaiser Permanente 
physicians do not see sales representatives.
There is also a need to encourage reform of the 
regulatory landscape. This could include introducing 
limits to some forms of promotion of new drugs by 
the industry, promoting active pharmacosurveillance, 
and also promoting the design of pragmatic 
randomised controlled trials, systematic observational 
research and comparative effectiveness research 
through public funding.
Assistant Professor Mintzes provided a detailed declaration 
of her interests (see Appendix 2 for details)
Conclusions
Key evidence needed to support patient care 
decisions is often lacking. In particular this can mean 
there is no information about:
 • whether the benefits of a new drug outweigh its 
harms
 • which groups of people do better or worse using 
the drug
 • how the new drug compares with existing 
alternatives
 • what the population-level outcomes are
 • patients’ lived experiences and priorities for the 
drug and the disease.
Is the dream of evidence-based medicine sinking like 
the Titanic? No – but there are key areas for policy 
change, including:
 • priority-setting for research
 • introducing changes to manage industry 
sponsorship of clinical trials and the publication of 
results, reporting and dissemination
 • ensuring a transparent link between what 
regulators know and publicly available clinical 
evidence
 • promoting public access to research protocols and 
results, especially through the use of clinical trial 
registries
 • ensuring that advisory committees considering the 
use of new drugs meet in public
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PANEL DISCUSSION
Therapeutic independence and  
evidence-based medicine
Panel discussion
issues, including definitions of ‘independence’, are 
often complex.
There is a need to ensure that guideline development 
groups include wide representation from different 
health disciplines and people with different 
backgrounds and skills, and it should be clear where 
there are contrasts between sets of norms, values 
and ideals. This will allow members of guideline 
development groups and committees to get a wider 
picture of each contributor’s influences.
The issue of conflict of interest is not a solely medical/
health issue. For example, it is important that all 
influences and interests are known when members of 
a jury are selected. Directors and businesses also have 
formalised processes for declaring and managing 
conflicts. People submitting journal articles are also 
required to make declarations in accordance with the 
statements on conflicts of interest in medical journals 
by the World Association of Medical Editors and the 
International Committee of Medical Journal Editors. 
Medical journals need to be checked to ensure they 
follow their own code of ethics and actively enforce 
their policies with contributors.
There is a need to educate clinicians and consumers 
in critical appraisal of intervention studies and other 
types of studies, in part to enable awareness of the 
pervasive risk of bias from diverse sources.
Driving the research agenda
There are opportunities for guideline developers 
such as Therapeutic Guidelines in Australia to identify 
areas where further research is needed to fully 
cover the spectrum of information required in each 
therapeutic area. There could also be opportunities 
for guideline developers to have a role in setting the 
research agenda and in actively promoting changes in 
healthcare practice.
Role of ethics committees in  
research design
Is there a need to reinforce the critical capacities 
of the people on ethics committees? Do the ethics 
committees and researchers actively work within the 
framework of ethical principles for medical research 
described in the Helsinki Declaration?
Each panellist was invited to comment on the 
issues raised by Professor Silvio Garattini and 
Assistant Professor Barbara Mintzes in their earlier 
presentations, and comments from the forum 
participants were also invited.
Quality of data used in guidelines
To what extent are there sufficient mechanisms to 
discern between biased and independent data?
In the area of psychiatric medicine there has 
been considerable concern about the influence of 
commercial interests on the data used to register 
new medications, especially for ‘atypical’ (second- 
and third-generation) antipsychotics, as well as 
selective serotonin reuptake inhibitors and related 
antidepressants.
There are also widespread concerns about the lack 
of follow-up data on the long-term effects of newly 
registered therapeutic products. Regulators need 
to have ways to follow up effectiveness and safety 
data on a routine basis. Some of the mechanisms for 
assessing the quality of the data include consideration 
of the comparative effectiveness of the new drugs, 
but often this information is not available because 
of the trial design used, deficient ascertainment and 
incomplete reporting.
Allocation of research grants
Does the process used to allocate research grants and 
funding naturally encourage researchers to ‘talk up’ 
their study and the results?
There is considerable support for finding ways to 
fund investigator-initiated trials. Full disclosure of all 
drug company links and funding should be required. 
Fines and other penalties should be imposed if drug 
companies falsify data. Some of the fines could be 
used to fund investigator-initiated trials.
Identifying conflicts of interest
There are persisting issues of real and perceived 
conflicts of interest. Some people will not be able to 
easily identify whether they have conflicts, or will have 
interests they are not aware of (e.g. they may not 
know where their university gets its funding sources). 
People funded by government may also be influenced 
by the government's current policy imperatives. These 
Panel members 
Professor Rachelle 
Buchbinder
Professor Terry Campbell
Professor Silvio Garattini
Associate Professor  
David Menkes
Assistant Professor  
Barbara Mintzes
Dr Philipa Rothfield
Associate Professor  
Ian Scott
Moderator
Professor Paul Komesaroff
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PANEL DISCUSSION
Publishing clinical trial data
How can we introduce greater transparency into the 
data relating to drugs? Who should be the agent 
for change? Who are the critical players/partners/
stakeholders to lead the call for change? What are the 
preconditions for change? What are the barriers to 
introducing these changes?
The government has some awareness of these issues 
and has recently established a website for registering 
clinical trials (www.anzctr.org.au). At this stage 
there is no requirement to publish the results of all 
registered trials.
There are three main areas where change is needed:
1. Regulators should make publicly available all of the 
information they have access to when approving 
a drug.
2. Regulators should require applicants seeking 
approval for their drugs to demonstrate that 
the new drug has a proven therapeutic benefit 
compared to existing treatments.
3. Governments should take steps to increase the 
number of investigator-driven clinical trials.
A wider role for Therapeutic 
Guidelines Limited
Is there a wider role for Therapeutic Guidelines in 
progressing these discussions? For example:
 • Would it be possible for Therapeutic Guidelines 
to take a leadership role in establishing gold 
standards of behaviour and good governance in 
clinical research and to provide advice to other 
Australian guideline developers on ways to 
manage conflicts of interest?
 • Is there a wider global role for Therapeutic 
Guidelines and its products?
 • Can Therapeutic Guidelines extend its purely 
scientific approach to include wider contextual 
issues such as social determinants?
 • Can Therapeutic Guidelines take on a role 
promoting a wider understanding of the value 
of guidelines and also teaching critical appraisal 
skills?
 • Does Therapeutic Guidelines have a role in 
improving the uptake of guidelines?
 • Can Therapeutic Guidelines begin to develop 
guidelines that address comorbidities?
Ethics committees have the ability to change or seek 
modifications to protocols or the design of studies 
they are considering. However, this can be difficult, 
especially when multicentre approvals are being 
considered. There was discussion about whether 
the ethics committees could introduce a process of 
independent scientific review of study design before 
considering proposals. NPS MedicineWise has recently 
been working with ethics committees to help them 
access high quality information about medications. 
There are also plans to change the structure of ethics 
committees around Australia. This might include 
the opportunity to provide training and information 
to committee members to ensure they understand 
issues associated with study design and the need for 
transparency and independence.
Addressing the problem of 
overdiagnosis
The problem of overdiagnosis must be addressed by 
guideline developers. The British Medical Journal1 and 
the Cochrane Collaboration are actively discussing 
and debating the growth of new diseases and the 
medicalisation of normal human development and 
ageing being promoted by the pharmaceutical 
industry and other vested interests.
Influence of consumers
The influence of consumers is seen as vital in all parts 
of the guideline development process. If there is going 
to be real change, it is important to recognise that 
patients and consumers are at the heart of the system 
and that they matter the most. Consumers must be 
given credit for being able to understand and digest 
information about their health. They want to know 
what treatments are going to do, how they work, how 
long they will take to work and what the risks and 
benefits are.
The Cochrane Colloquium works actively and 
effectively with consumers. It is useful to involve 
consumers in the design of every trial so that 
researchers and funders know that the right 
questions are being asked. For example, in the area 
of musculoskeletal medicine many consumers want 
to know basic information that will help them in their 
daily lives, such as ‘what is the best kind of mattress 
to help reduce or manage back pain?’, but this topic is 
not well covered by research.
The important issue is how to improve the quality of 
science and to take the focus away from the product 
and instead to focus on the needs of the person.
1. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: 
how to stop harming the healthy. BMJ 2012;344:e3502.
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Interpreting the evidence:  
Balancing truth, facts, values and interests
The case of Galileo
Galileo Galilei lived from 1564 to 1642. A great 
Italian scientist, he was the originator of modern 
physics. Many scientists believe that Galileo's work 
was plainly ‘true’, and that through the power of 
his intellect and logic he was able to supplant the 
erstwhile Aristotelian view of the world with a 
new, mathematical one. The view of succeeding 
generations was to seek objective truth, but this is 
not how it happened. 
Galileo was a great innovator and truly one of the 
great imaginative heroes of human history. However, 
his theories came to be accepted not primarily on the 
basis of the strength of his thought and observation, 
but on abstraction, a new language, the question of 
empirical validation. Galileo published a number of 
articles in the early 17th century strongly supporting 
the Copernican theory that the earth circled the sun 
(heliocentrism). These ideas were seen by church 
authorities as profoundly disruptive of the existing 
intellectual status quo and the church's teachings –  
and they therefore had a wide set of social 
implications. From the time Galileo wrote The Starry 
Messenger in 1610 the church took steps to shut 
him up and he was subject to harassment from the 
authorities (especially the ecclesiastical authorities) for 
the rest of his life. The authorities understood that the 
new ideas Galileo was writing about were dangerous, 
that his propositions were mere representation 
of objective facts, but that they carried profound, 
potentially uncontainable social implications for 
political authority.
In 1633 Galileo was tried before a formal inquisition 
for promoting the views of heliocentrism. He was 
found guilty, placed under house arrest for the rest 
of his life, and made to recant. They showed him 
the instruments of torture and told him to imagine 
what would happen if he did not recant. They knew 
their man and this was all they needed to do. Galileo 
recanted, even though he continued writing in secret 
and was able to arrange for his manuscripts to be 
smuggled to safety, where they were subsequently 
published.
Today's school students are taught that the strength 
of Galileo's theory lay purely in the fact that, 
compared to the Aristotelian orthodoxy, it carried 
greater empirical validity and was more closely in 
Decisions taken in scientific and clinical settings are 
subject to complex influences. The ethos of science 
as a disinterested pursuit of objective truth is at 
best imperfectly realised in practice. As a starting 
point, clinicians are not scientists; there is always a 
major contribution of clinical judgement to all health 
encounters. Ethical and social values, and personal, 
context-dependent characteristics are all taken into 
account in any interaction.
Two examples will be used to illustrate these points – 
the case of Galileo and that of hormone ‘replacement’ 
therapy (HRT) after menopause.
The concept of evidence has been discussed widely. 
It can be taken for granted that there are two levels 
of evidence, which are associated with very different 
logical processes:
 • Large-scale population data – where 
epidemiological studies, laboratory studies, in vivo 
experiments and randomised controlled trials are 
conducted
 • Local, individual clinical decision making – these 
considerations draw on large-scale evidence and 
on local clinical experience and wisdom.
Both approaches are associated with a mix of facts 
and interpretations. Local, individual clinical decision 
making is where actual decisions are made and 
actions are taken in consultation with the patient.
There are separate activities and concepts of 
knowledge with different standards for ‘truth’. Clinical 
decision relies on two sets of transitions to make 
sense of (or convert) the data that are relevant. This 
is complicated. The clinician must move between 
the data and their interpretations, and between the 
level of scientific evidence and the local, individual 
decisions that are made every day in the clinic.
Clearly, clinical decisions are influenced by the 
interpretation of the data collected in the controlled 
setting of scientific experimentation. These 
interpretations are not, as they are often presented 
to be, objective, disinterested, a pure and simple 
reflection of the facts, unbiased or unaffected by 
personal or local cultural beliefs or prejudices. Rather, 
the process of scientific interpretation is always 
deeply affected by such factors. Scientific facts 
always exist in a social context and their validity 
depends on this context.
Professor Paul Komesaroff
Professor of Medicine and 
Director of the Centre for 
Ethics in Medicine and 
Society 
Monash University 
Melbourne
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which can be ruthless and even violent. In Galileo’s 
case, he fought hard and, despite the setbacks, was 
eventually victorious, even if in his case the full victory 
came only posthumously.
The case of hormone therapy after 
menopause
In the 1930s scientific studies showed that 
administering oestrogen to mice could promote the 
development of breast cancer. Despite this, there was 
a strong interest in promoting oestrogens for women, 
starting in the 1960s. The American psychologist 
Robert Wilson initiated the modern emphasis on 
the use of hormone therapy in his book Feminine 
Forever. In today's terms this book is misogynistic, 
but at the time it was very popular, selling more than 
100 000 copies, with the claim that menopause was 
‘preventable’:
Every woman alive today has the option of 
remaining feminine forever… No longer need 
she fret about the cruel irony of women 
aging faster than men. It is simply no longer 
true that the sexuality of a woman past forty 
necessarily declines more rapidly than that of 
her husband.
All postmenopausal women are castrates… 
[but with HRT] a woman’s breasts and genital 
organs will not shrivel. She will be much more 
pleasant to live with and will not become dull 
and unattractive.
An oestrogen-rich woman capable of being 
physically and emotionally fulfilled by her 
husband … is least likely to go afield in search 
of casual encounters.
Robert Wilson, Feminine Forever (1966)
In the 1970s the word ‘replacement’ was inserted in 
the expression ‘hormone replacement therapy’ as 
an industry marketing strategy to make menopause 
appear as a pathological condition that required drugs 
to correct it. The pharmaceutical companies wanted 
HRT use to seem more acceptable and natural and to 
create the impression that older women needed to 
restore their hormones to premenopausal levels. The 
addition of this word turned out to be a very good 
investment, ultimately generating countless billions of 
dollars in sales of HRT.
Over the succeeding decades a great deal of 
scientific evidence has emerged about the actions 
of oestrogens and their effects on bones, the 
cardiovascular system, the neurological system, 
breast and uterus. We now know a lot about the way 
these hormones work.
During the 1990s HRT became widely accepted 
as a key treatment for menopause. The number 
accord with objective reality. In reality, the opposite 
was the case. Galileo's theory – at least in its early 
stages – was actually empirically inferior to the 
Aristotelian system. Everyone knows, after all, that the 
first law of motion – that a body in motion tends to 
remain in motion – is never borne out in fact. Rather, 
the Aristotelian idea of inertia – that if you push a 
body it will stop – is what we observe on earth in 
every real instance. In reality, Galileo's theory was not 
empirically valid. It was abstract and contrary to the 
facts. Indeed, this was its great innovation. Galileo 
discovered not the concept of empirical science, but a 
new idealised language, the language of mathematics, 
in which the empirical questions could be formulated. 
The success of the theory was dependent not on its 
‘objective’ validity, but on other factors related to 
knowledge, philosophy, society and politics.
Galileo was attacked, but he fought back in his 
writings. He took the struggle to the streets, writing 
popular works, not just in Latin, but also in Italian, the 
language of the common people. In a book on the 
arguments for and against heliocentrism (Dialogue 
Concerning the Two Chief World Systems) he sought 
to obtain the support not of the effete intelligentsia, 
but of the common people. There are two main 
characters in the book: Sagredo, who is Galileo 
himself, and a second person called Simplicius in Latin 
or Simplicio in Italian, who represents the Aristotelian 
view (that the sun revolved around the earth) and 
speaks in phrases used by the Pope. The name 
Simplicio in Italian has the connotation of a simpleton, 
and the portrayal of this character served to cast 
greater doubt on the established ideas amongst the 
local readers of the book and ensured readers were 
on Galileo's side.
Galileo's struggles to get his ideas accepted show 
how science, culture and society are intertwined. 
They draw attention to the fact that the success of 
a scientific theory – its acceptance or rejection, its 
capacity to generate approval or hostility – is not 
determined merely by its philosophical or empirical 
value, but also crucially by the complex social and 
political frame within which it is embedded.
Scientific meanings are subject to and dependent  
on social attitudes, prejudices and belief systems. 
People can find ways to convince themselves 
that a particular view is true depending on their 
personal attitudes. It is not the case that the process 
of understanding science, data and the world, is 
detached and objective. It is always rooted in local 
vested interests. Science and medicine cannot be 
separated from the contemporary cultural debates. 
This is the essence of what Galileo discovered. The 
success of a theory depends on social struggles, 
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coronary heart disease, stroke and pulmonary 
embolism in the study participants. Two years later 
the oestrogen only arm was also stopped because it 
increased the risk of stroke, decreased the risk of hip 
fracture and did not affect coronary heart disease 
incidence. By this time several other large trials had 
been published that suggested the assumptions about 
the benefits and risks of hormone therapy may have 
been misplaced.
The conclusions of the WHI generated a remarkable 
situation. Guidelines produced by experts had been 
widely propagated supporting the use of hormone 
therapies. However, now data were available that 
called into question the basic assumptions on which 
those guidelines had been founded. The experts, of 
course, were scientists so one would expect that they 
would respond to the new knowledge by revising 
the guidelines to incorporate the current insights 
and introduce appropriate notes of uncertainty and 
caution. Correct? Unfortunately, no. This did not 
happen. The guideline developers mostly did not 
change their attitudes. Instead, they mounted a 
vigorous campaign – which even continues today – to 
attack and refute the study conclusions.
To avoid misunderstanding, it is important to 
emphasise that debates about the validity of clinical 
studies and the interpretation of their results are part 
of the legitimate discourse of science. However, in this 
case what is remarkable is that despite the significant 
size and rigour of the WHI trial and the clarity of its 
outcomes, and the subsequent accumulation of a 
great deal of supporting data, many of the committed 
advocates of hormone therapy refused to alter 
their positions to any significant degree. Instead 
their response was not to question their own prior 
assumptions, but to find arguments to support why 
the WHI had to be wrong. For example, it was argued 
that the wrong population was used (e.g. the study 
participants were too old, only North American, 
and included smokers), that the wrong hormonal 
preparation was administered, that the interpretation 
of the data was wrong, and that the wrong methods 
were used in the design of the trial.
In a 10-year review of the WHI results published in 
2012, the original view about breast cancer in the 
oestrogen plus progestogen arm was validated by the 
long-term follow-up. In the oestrogen-only arm the 
breast cancer outcomes are reported as equivocal, 
the cardiovascular outcomes were negative, and 
oestrogen was shown to be harmful in Alzheimer's 
disease prevention.
However, even now, few of the original proponents 
of hormone therapy have changed their minds. 
Instead, they promote arguments not based on 
of prescriptions for oestrogen-based therapies 
skyrocketed in the industrialised world. Guidelines 
issued by menopause societies in Australia, North 
America and Europe actively promoted HRT.
The comfortable consensus was exploded in 2002 
with the publication of the first results of the Women's 
Health Initiative (WHI). The WHI was, in its time, 
the largest and most expensive clinical trial ever, 
involving a total of 160 000 participants and running 
for more than 10 years. It began in the early 1990s 
as a response to rising discomfort about the lack of 
clinical data and concern that some of the benefits of 
HRT were exaggerated. The WHI evoked considerable 
opposition when it started, with some advocates for 
hormone therapies even arguing that it was ‘unethical’ 
to continue testing these treatments because so much 
was already known about them and the agreement 
about their effectiveness and safety was so strong.
The WHI hormone therapy study had two arms – an 
oestrogen plus progestogen arm that ceased in July 
2002, and an oestrogen-only arm that ceased in 
February 2004. The oestrogen plus progestogen arm 
was stopped because the trial showed an increased 
risk of invasive breast cancer and an increase in 
Examples of clinical recommendations from the 1990s  
June 1990: ‘The cardiovascular benefits of Premarin may outweigh the risks 
depending on the individual patient’s risk profile for various oestrogen-related 
diseases and conditions.’ 1
1991: ‘Epidemiological evidence is accumulating that postmenopausal oestrogen 
therapy reduces the risk of cardiovascular disease and stroke by between 30 and 
70% even in the presence of established risk factors.’ 2 
1992: ‘Oestrogen is cardioprotective for women. Not only does it have a beneficial 
effect on the circulating blood lipid fractions, but it is now established that oestrogen 
has a positive influence in preventing the deposit of cholesterol in the arterial 
endothelium. It also induces vasodilation, increases peripheral blood flow and leads 
to a fall in blood pressure. The use of oestrogen to reduce cardiovascular disease far 
outweighs any potential adverse changes.’ 3 
1992: ‘All women…should consider preventive hormone therapy.’ 10 to 20 years of 
therapy were recommended for ‘maximum benefit’. 4 
1993: ‘All postmenopausal women, barring a medical contraindication like breast 
cancer, should take HRT for life.’ 5 
1994: ‘HRT can reduce the incidence of CHD in postmenopausal women by 50%… 
HRT reverses the increased fat distribution that results from loss of ovarian function 
at the menopause. HRT may also (result) in a reduction in arterial thrombosis.’ 6
1996: ‘There is now good population-based evidence that HRT in postmenopausal 
women reduces the incidence of CHD, perhaps by up to 50%. HRT should therefore 
now be considered for use in postmenopausal women with established CHD risk.’ 7 
2000: ‘Today, HRT may be used for the primary prevention of CVD. (T)here is no 
compelling evidence for discontinuing – or indeed not initiating – HRT in women 
without CVD because of concern about cardiovascular risk.’ 8 
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purely to the careful, dispassionate and disinterested 
assessment of the facts. Rather, they are dependent 
on other factors operating outside of scientific 
discourse. They are subject to the influences of culture 
and ideology, of personal beliefs and reputation, of the 
vested interests of the pharmaceutical industry and 
medical practitioners, of prevailing social prejudices, 
and of politics and power. Of course, these arguments 
apply to both sides. The debates about hormone 
therapy after menopause – just like the debates about 
the two world systems four hundred years earlier – 
are not fought out merely in the domain of science.
These are culture wars. The battle, as in the case of 
Galileo, has been – and is still being – contested not 
just in the halls of academia, but also in the streets, in 
the newspapers, on television, through the internet. 
Every new finding is accompanied by a press release, 
often tendentious.
As with Galileo, with hormone therapy there are many 
interests and influences at play. The field is not one 
of pure science in the idealised sense. The ‘ethos’ of 
science is imperfectly realised in practice. Despite the 
proclaimed commitment to evidence and an open 
scepticism, the reality is very different.
This is the sad and sobering moral of my story, but 
it should not be a cause for despair. Rather, those 
who work (through guidelines or other means) to 
improve clinical practice and to effect changes in 
policy merely need to recognise the complexity of the 
environment within which they are operating and to 
add the factors I have been discussing as additional 
variables to be taken into account. There is no pure 
science. There is no simple, incontestable objective 
truth, the facts never speak for themselves. Rather, we 
always have to make judgments from interest-laden 
points of view. Whether we like it or not, the process 
of responsible decision making – ours and everyone 
else’s – always involves the establishment of a careful 
balance between truth, facts, values and interests.
Professor Komesaroff provided a detailed declaration of his 
interests (see Appendix 2 for details)
evidence, or based on studies that provide limited 
(often flawed) data that appear to support their case. 
For example, a recent Danish study9 (which included 
1000 people with questionable recruitment strategies 
and an idiosyncratic end point) suggested possible 
cardiovascular benefits in a particular population and 
was widely promoted as refuting the results of the 
entire WHI program. At the same time, the popular 
media – the same media that actively supported and 
encouraged the use of HRT – have continued to cast 
doubt on the conclusions of the WHI and a large 
number of other studies that now support its broad 
conclusions, and to promote new studies of lower 
quality or study design in order to demonstrate to 
the public that there is positive news for the use of 
HRT. Headlines abound, such as ‘Flaws in Major US 
Study on HRT’, ‘HRT gets another chance’, ‘Doctors 
to rethink benefits of HRT after study shows that 
oestrogen may protect women against breast cancer’, 
‘Call for NIH to revise recommendations on HRT’, 
‘A wasted decade: how one HRT scare has caused 
countless women ten years of needless suffering’ and 
‘Expert calls for inquiry into the NIH’.
I do not want to suggest that the evidence, one way 
or the other, about hormone therapy is clear-cut. On 
the contrary, there is much that remains uncertain 
and there are key issues that await clarification from 
future scientific studies, involving both laboratory 
experiments and clinical studies. However, the point 
I want to make is that the original uncritical support 
for hormone therapy was not based on evidence, and 
the appearance of new evidence was insufficient in 
many cases to change this support. Many of the most 
zealous advocates of the therapy have retained their 
commitment, even in the face of considerable – if not 
completely conclusive – data to the contrary.
Conclusion
I hope that the parallel with the case of Galileo is clear. 
Even today, the informed opinion of experts and the 
debates around contending theories are not subject 
1. Wyeth advertisement.
2. Hillard TC, Whitcroft S, Ellerington MC, Whitehead MI. 
The long-term risks and benefits of hormone replacement 
therapy. J Clin Pharm Ther 1991;16:231-45.
3. Wren BG. HRT and the cardiovascular system.  
Aust Fam Physician 1992;21:226-9.
4. American of College of Physicians leaflet.
5. The American College of Obstetrics and Gynecology 
recommendation.
6. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. 
Hormone replacement therapy and the cardiovascular 
system. Nonlipid effects. Drugs 1994;47 Suppl 2:35-41.
7. Stevenson JC. Mechanisms whereby oestrogens influence 
arterial health. Eur J Obstet Gynecol Reprod Biol 
1996;65:39-42.
8. Genazzani AR, Gambacciani M; International Menopause 
Society. Controversial issues in climacteric medicine I. 
Cardiovascular disease and hormone replacement therapy. 
International Menopause Society Expert Workshop. 13-16 
October 2000, Royal Society of Medicine, London, UK. 
Climacteric 2000;3:233-40.
9. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, 
Mosekilde L, et al. Effect of hormone replacement therapy 
on cardiovascular events in recently postmenopausal 
women: randomised trial. BMJ 2012;345:e6409. 
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Experts and competing interests
 • 15 universities did not require regular declarations 
from staff and only four required annual 
declarations
 • Only eight universities maintained a central 
register of staff declarations
 • Only six universities had some mechanism in place 
that allowed members of the public to access 
information from their register
 • None required that staff place their declarations 
on their website profiles and none had policies 
that indicated staff should declare conflicts when 
making public comment. These can be recovered 
through Freedom of Information processes, but it 
is hard work.
Recent National Health and Medical Research 
Council-funded studies (NHMRC 457497 and 141772) 
have been conducted to seek more detail on the 
relationships and interactions between industry 
and Australian specialists. The study involved 1500 
clinicians and showed that:
 • 96% had accepted gifts (the value of gifts was 
higher if the physician was in an active research 
relationship with that company or was on the 
advisory panel of that company)
 • 84% had attended a sponsored symposium or 
product launch (as distinct from a conference)
 • 52% had accepted travel sponsorship and 30% had 
accepted travel support for their partner
 • 23% had been a member of an industry advisory 
panel
 • 7% owned shares in pharmaceutical companies 
that produced drugs that they prescribed
 • 6% had acted as a paid consultant.
The study also investigated the concerns of 
respondents about industry-funded research. These 
concerns, by percentage of respondents, included:
 • premature termination of trials (most of these 
appeared justifiable e.g. adverse events) – 14% (114) 
 • first draft of paper written by sponsor or 
ghostwritten – 12% (100) 
 • unreasonable delay in publication – 6.7% (55) 
 • failure to publish negative findings – 5.2% (41) 
 • draft of paper editing to make the drug look better 
– 2.7% (22)
 • concealment of results – 2.2% (18) 
 • inappropriate alteration of data  – 0.9% (7).
What do people understand about the issues that 
influence their judgment and decision making? What 
point is served by declarations of interest? There are a 
wide range of people with different interests, ranging 
from professionals, patient organisations, medical 
students and the public. How much information 
is needed and what needs to be done beyond the 
‘declaration’ to manage the interests?
Contacts with industry are vast and multidirectional 
(i.e. clinicians and researchers approach industry 
as much as industry approaches clinicians and 
researchers).There is much less data in Australia about 
the extent of interactions between the health sector 
and the pharmaceutical industry than in the USA. A 
US study showed that:
 • 85% of professional organisations are sponsored 
by, or receive advertising revenue from, the 
pharmaceutical industry.
 • More than 80% of patient/consumer groups 
receive support from the pharmaceutical  
industry.
 • Many medical students have accepted gifts from 
industry and had extensive contact with industry-
sponsored education, promotional materials and 
data before graduation.
 • The public also engage with industry through 
direct-to-consumer activity – despite this being 
prohibited in Australia.
In 2009 an American Medical Student Association 
PharmFree Scorecard survey asked US universities 
if they had conflict of interest policies. The domains 
of interest included gifts, consulting relationships, 
industry-funded speaking relationships, disclosure, 
on-site educational activities, medical school 
curriculum, and compensation for attendance at 
meetings. One-third of the universities refused to 
answer the question. The American Medical Student 
Association gave permission for their methodology 
to be used to assess conflict of interest policies in 
Australian medical schools. The results were published 
in 20111 and showed that the majority of Australian 
universities, as with those in the USA, scored very 
poorly.
Another recent study looked more broadly. The 
Australian University Conflict of Interest Survey2 
showed that nearly 30% (n=12) of universities declined 
to provide any information. Of those that did provide 
information, most (n=27) had policies on staff’s 
competing interests:
Associate Professor Ian 
Kerridge
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Journals have evolved into laundering 
operations for the pharmaceutical industry. 
Richard Horton, Lancet
Journals have been co-opted by industry.
Marcia Angell 
New England Journal of Medicine
Medical journals are an extension of the 
pharmaceutical industry.
Richard Smith, British Medical Journal
There is a cycle of dependency between 
journals and the pharmaceutical industry.
PLoS Editors
Assessing and managing interests  
in medicine
There is now a huge amount written about conflicts 
of interest. Many professional bodies, colleges, 
universities, research institutes and industry 
organisations and networks now have codes of ethics 
and conflict of interest policies, although these are of 
variable quality and most remain in the private rather 
than the public sphere.
Three of my own experiences illustrate both the 
importance of having some means for thinking 
through conflicts of interest and the difficulties 
associated with assessing and managing them.
Development of embryonic stem cells and 
human cloning legislation
In 2005 to 2006 I was involved in the Lockhardt 
Committee, a Legislative Review Committee 
established by the Commonwealth Government to 
review the Acts relating to human cloning and embryo 
research. One of our tasks was to draw up a view 
regarding progress or reform in this area  
that was consistent with ‘community values’. It 
became clear that, on this issue (and undoubtedly 
on others), there was no single community or single 
community view or values. Instead, there were 
many communities and many values and interests, 
and these were often diverse and sometimes 
incommensurable. Also, there was not a single 
person in the community who was not concurrently 
a member of many different ‘communities’, each of 
which had its own norms, values and language. A 
person was simultaneously a research scientist, a 
doctor, a mother, a Catholic and a friend of someone 
with a disease that may, in the future, be helped by 
stem cell research. The task for us as a committee, 
and also for every person when deciding how they 
should act or behave or vote, was to reflect on the 
multiplicity of values and to identify what these 
interests are, how salient they are, where upon a 
The potential adverse consequences of 
pharmaceutical-industry sponsorship of research have 
been extensively described. They include:
 • increased costs of care
 • distortion of care, erosion of rational prescribing 
and quality use of medicines
 • distortion of research agenda (creation of 
the ‘90/10 divide’ whereby 90% of research 
is conducted in diseases that affect 10% of 
the world’s population – those able to afford 
pharmacotherapies)
 • distortion of evidence (with the results of 
sponsored studies consistently being more often 
favourable towards the sponsored therapy under 
investigation)
 • distortion of research question (reduction in  
‘head-to-head’ studies, particularly of competitor 
drugs)
 • distortion of research methods (move from 
superiority to non-inferiority trials)
 • selective reporting of data favourable to product
 • loss of researchers’ independence and integrity
 • creation of multiple ties and conflicts of interest
 • creation of gift relationships
 • increase in secrecy in medicine and research
 • delay or non-publication of key findings 
for commercial reasons (such as has been 
documented with studies of COX-2 inhibitors and 
selective serotonin reuptake inhibitors)
 • erosion of public trust in research, medicine and 
health professionals.
While these harms work in different ways in different 
contexts, ultimately they all have the capacity to 
subvert the (proper) goals of medicine, health 
education and biomedical research.
This level of systematic bias in medicine is a challenge 
for all those engaged in health, but it is a particular 
problem for evidence-based practice, which 
emphasises and relies on published evidence. If the 
data on which evidence-based practice is founded are 
corrupted, then so is practice itself.
Concern about this level of pharmaceutical industry 
involvement in research, education and clinical care is 
not limited to liberal critics of medicine, but is shared 
by many of those who have an interest in the quality 
of medicine and biomedical science. It is noteworthy 
that past and present editors of many of the world’s 
major medical journals have noted the adverse impact 
that industry sponsorship has had (and continues to 
have) on the scientific record and on the integrity of 
the profession.
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In 2011 the well-known psychiatrist, mental health 
advocate and public intellectual Professor Ian Hickie 
co-authored a narrative review of melatonin-based 
therapies (agomelatine) for depression in the Lancet.3 
In the paper both authors disclosed ties (financial 
and professional) with the manufacturer, Servier. This 
paper provoked a firestorm of criticism in the Lancet, 
lay press, and social media about the disclosure of 
interests. The criticism included both empirical claims 
– that the authors misreported the tolerability/efficacy 
of agomelatine – as well as moral claims – that the 
authors were conflicted or biased or that they, or 
Servier, may have benefited from publication.
Hickie and Rodgers penned a spirited response4 
defending their findings, their professional ethics and 
their compliance with the Lancet’s disclosure policies.
This is not the first time that psychiatry has 
featured in discussions around the links between 
the pharmaceutical industry and the medical 
profession. Over the past two decades there have 
been innumerable occasions where concerns have 
been raised about the links between psychiatry 
and industry (likely a consequence of the nature 
and prevalence of mental illness and the vagaries 
surrounding psychiatric diagnosis). In recent times, 
for example, concerns have been raised about the 
impact of commercial interest on the revisions to 
the DSM-5. These concerns have included questions 
over the definition and diagnosis of illness, issues 
of overdiagnosis, overt drug promotion and non-
disclosure of pecuniary conflicts of interest. For  
the Working Groups revising DSM-5, 67% of the  
Mood Disorders Work Group, 83% of the Psychotic  
Disorders Work Group, and 100% of the Sleep–Wake  
Disorders Work Group had ties to manufacturers of 
medications used to treat these disorders.5
There is no doubt that Professor Hickie is entangled 
in a web of interests, but in this regard he is likely no 
different to any other major researcher or director of 
a research institute. As an academic researcher, well-
respected clinical psychiatrist, public advocate and 
director of a research centre he is expected to create 
and sustain links with industry, forge public–private 
partnerships, and develop research that inevitably 
engages with industry.
The lesson here is that each social role carries with it 
a series of moral, social and professional imperatives 
that one assumes when one adopts that role, and 
these are often difficult to balance. While most of 
the time each of us can balance these different roles 
easily, in some situations conflicts may emerge – 
conflicts that may or may not have very serious 
implications for science and practice.
continuum of interests they lie, and how they should 
be managed – particularly when they appear to be 
incommensurable.
The lesson here is that one always has multiple 
interests simply by virtue of having different social 
roles, and sometimes these are problematic and 
sometimes they are not. The task for guideline 
developers is to identify the interests at play and then 
to consider, through open and transparent debate, 
whether or not these interests create a conflict or put 
at risk the integrity or rigour of the guideline.
Faith
In recent times I have had cause to think about the 
relevance of faith to medicine and health policy. Faith 
is important to people, their lives and families. It 
comes with a set of values, rituals, authorised dogma 
and hierarchies of decision making that influence 
the way people of faith may approach any issue or 
situation. Faith, in and of itself, does not represent 
a conflict of interest or necessitate exclusion from 
discussions about health policy. Indeed, ethics 
committees are required to include representatives 
from pastoral care or faith in their membership. And 
faith undoubtedly contributes to thinking about values 
or beliefs or the impacts of health policy. However, 
while there is a tendency to privilege faith – to 
suggest that it is never appropriate to exclude people 
of faith from policy-making on the grounds that they 
have a conflict of interest – this seems not to be 
true. Surely a Jehovah’s Witness has an unavoidable 
conflict when it comes to blood policy, a Scientologist 
has an unavoidable conflict when it comes to mental 
health policy, and a Catholic priest has an unavoidable 
conflict when it comes to determining policy on 
access to reproductive technology or third-trimester 
termination of pregnancy?
While one would not seek to exclude people of faith 
or be deaf to their values, for those charged with 
developing guidelines, the question is where relevant 
expertise (including representatives from industry or 
researchers with extensive ties to industry) should 
sit. Should the person have a role in the development 
of expert guidelines, or should they be kept distant 
but be invited to give an expert perspective – an 
interested perspective – via submission or review?
Interests and expertise: The 
ubiquitous nature of competing 
interest in contemporary healthcare 
and research
This year I was invited to write a commentary on 
the issues surrounding a well-publicised public 
and professional debate about conflict of interest. 
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We must also openly establish 'interests' as a 
conversation and establish rigorous, transparent and 
professionally accepted processes for discussing, 
assessing and managing competing interests. These 
conversations will only happen, of course, if the 
relevant communities (be they industry, scientific or 
research communities) have a culture that respects 
discourse on these issues, and are prepared to 
establish guidance regarding what sort of disclosure 
and management of the interests is required. This 
guidance will need to make clear not only when and 
how interests should be declared and how relevant 
interests should be assessed, but what relationships 
may or may not be acceptable and how competing 
interests should be managed – by declaration alone, 
consultation, collaboration, abstention, delegation, 
divestment or separation.
Importantly, guidance on assessing and managing 
competing interests should attend both to pecuniary 
and non-pecuniary interests. While we have made 
some progress in thinking about financial conflicts 
of interest, much less is known about non-pecuniary 
interests and how we should manage them. In my 
view it is very likely that non-pecuniary interests 
(which include political influences, publication, status, 
professional recognition, academic progression, and 
belonging to a professional or academic community) 
are much more important ‘drivers’ than financial 
interests and rewards.
There are no clear solutions, but it is clear that we 
need to think differently about interests, we need to 
think more rigorously about interests and make the 
discussion about facts and values rather than personal 
failings or psychopathology. We also need to have 
these discussions in public spheres rather than purely 
private ones.
Acknowledgments: Professor Ross Upshur, Dr Wendy 
Lipworth, Professor Paul Komesaroff, Emeritus Professor 
Miles Little and Dr Chris Jordens
Professor Kerridge provided a detailed declaration of his 
interests (see Appendix 2 for details)
Conclusion
‘Interests’ involve a commitment, goal or value arising 
out of a particular social role or practice. There is 
nothing wrong with interests per se. So rather than 
speaking of conflicts of interest we should speak 
of multiplicities of interests and accept that just as 
people have many roles they also have many interests 
– none of which has obviously greater a priori 
importance or weight. 
At any one time a person has a range of interests. For 
example, I am a clinician, teacher, director, colleague, 
collaborator, father and partner – all these roles have 
different demands and expectations attached to them 
and sometimes these interests collide.
The task for guideline developers and clinicians is 
to establish whether any one of these divergent 
interests constitutes a genuine conflict of interest 
(such that one's primary commitment at that time 
or in a particular context – e.g. research or design of 
guidelines/policy – is subverted or distorted) and to 
consider what should be done. This may be a function 
of the importance of the task and the necessity to 
separate interests. While this must be a matter for 
personal reflection and humble introspection, it must 
also be a public matter for discussion and discourse 
with relevant stakeholders.
In guideline development processes it is clear that it is 
not sufficient to simply disclose an interest and rely on 
that disclosure to resolve ethical concerns. Disclosure 
may obfuscate or provide moral licence and does 
not reduce the prevalence or impact of competing 
interests. Disclosure and transparency are, of course, 
important, but the idea that disclosure is sufficient to 
expunge the possibility of bias, or that responsibility 
for assessment lies with the public, readers and 
users, is naïve and morally inadequate. We need to 
go beyond this, and this requires that we develop 
a more sophisticated view of interests and that we 
‘de-psychopathologise’ conflict of interest and remove 
blame or ignominy from declarations.
1. Mason PR, Tattersall MH. Conflicts of interest: a review of 
institutional policy in Australian medical schools. Med J Aust 
2011;194:121-5. 
2. Chapman S, Morrell B, Forsyth R, Kerridge I, Stewart C. 
Policies and practices on competing interests of academic 
staff in Australian universities. Med J Aust 2012;196:452-6. 
3. Hickie IB, Rogers NL. Novel melatonin-based therapies: 
potential advances in the treatment of major depression. 
Lancet 2011;378:621-31. 
4. Serfaty M, Raven PW. Novel melatonin-based treatments for 
major depression [letter]. Lancet 2012;379:217-9. 
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Identifying and managing competing 
interests
Panel discussion
Consumers and practitioners want to trust health 
services and guidelines. In the past, the trust has 
been based on non-disclosure and placing a lot of 
faith in people to ‘do the right thing’, but there is now 
a strong clear call for disclosure on as many things 
as possible. There should also be more consumer 
representation and engagement on guideline teams. 
Where consumers represent organisations and 
decision-making bodies, the funding sources of those 
organisations should also be disclosed.
How to manage conflicts of interest
It is not possible to avoid the issues of bias in data  
and research. Agencies and guideline development 
teams need to choose people who are as independent 
as possible, and have transparent processes for 
them to follow. By having agreed processes, good 
people will not be discouraged from participation on 
guideline teams.
It might be useful to look at other sectors to see how 
they deal with conflict of interest issues. Does the 
jury system have processes that could help inform 
guideline processes for managing interests?
Is there a risk that disclosure could lull people into a 
false sense of confidence and assurance?
People with a range of values can bring a wealth 
of expertise to the development of a guideline. It 
is possible to separate out financial interests from 
expertise. There needs to be guidance about when 
people with ‘interests’ or expertise should be included 
or excluded from discussions – for example should 
a person involved in research about drugs or health 
services be part of a committee that approves that 
product or service? The American Thoracic Society 
has looked at these issues very carefully and has 
implemented a transparent and structured process 
that allows experts who have made disclosures to 
discuss the evidence and give their expert opinions, 
but excludes them from the final debate on the 
evidence and the formulation of recommendations. 
Also, the guideline panel is led by a methodologist 
rather than a clinical expert.
There are people with connections to industry who 
can nevertheless provide specialist opinions that add 
value and perspective to the discussion of a guideline. 
Each panellist was invited to comment on the issues 
raised by Professor Paul Komesaroff and Associate 
Professor Ian Kerridge in their earlier presentations, 
and comments from the forum participants were also 
invited.
Identifying pecuniary and non-
pecuniary interests
Issues of faith and religion are important to many 
people and are part of their make-up. Along with a 
number of other factors (such as their background 
and cultural perspectives), they contribute to each 
person's view of the world. It is incredibly complex, 
and most people are not aware of how their range 
of personal beliefs could influence decisions. When 
it comes to declaring interests, it is useful to declare 
faith as a possible duality of interest and to ask the 
group of people you are working with whether they 
believe it is significant enough to be a potential 
conflict of interest. If it is an issue, then one should 
disassociate oneself from the work.
By declaring the full spectrum of interests (financial, 
academic influence/kudos, professional or personal/
family ties) early in the process, others on a group or 
team have a chance to consider whether it is an issue 
and how it can be managed. It also makes clear to 
others that the conflict does not create an obligation 
through association.
Non-industry related conflicts should also be 
disclosed, and there should be transparency and 
discussion about the effect of an interest.
Do government links and funding create potential 
conflicts? This is a particular consideration in cases 
where the government might have an established 
policy it wants to have upheld, or where the 
government may be required to consider funding 
activities proposed by a guideline.
Another type of conflict arises when people have 
gone on public record for or against a particular 
form of care, treatment or product and may be seen 
as having a fixed view that will not be swayed by 
evidence or other information provided to a guideline 
committee.
Many interests and conflicts may be hard to quantify, 
but it is important to strive to be as transparent as 
possible.
Panel members 
Professor Chris Baggoley
Dr Peter Greenberg
Dr Suzanne Hill
Professor Robert Moulds
Professor Martin Tattersall
Dr Janet Wale
Moderator
Professor Paul Komesaroff
PANEL DISCUSSION
33www.australianprescriber.com
VOLUME 36 : SUPPLEMENT 2: 2013
in meetings to ensure that the Committee as a whole 
maintains a high level of independence.
In addition to managing the conflicts or perceived 
conflicts of people on guideline development teams, 
it is also important to ensure that the members are 
aware of other areas and risks of bias in assessing 
research findings.
Promoting trust
Guideline users want to have faith and belief in 
the scientific process and want to be sure that 
all reasonable care and scientific rigour has been 
applied to the guideline development. In a number 
of cases, guidelines are also used as training tools 
for new health practitioners. While there are a lot of 
competing kinds of information (such as activities 
funded by the pharmaceutical industry), there 
needs to be a way of assuring the users (including 
consumers) that guidelines have been developed 
using careful and independent processes. Trust and 
reputation of the guidelines are critical. It is important 
to users that the pecuniary interests, faith and beliefs 
of the guideline developers are clearly stated and 
managed, and that the evidence has been evaluated 
to assess the risk of bias.
Therapeutic Guidelines has a reputation for trusted, 
easy-to-access guidelines that are endorsed by 
professional colleges. Many guideline developers have 
a vested interest in either promoting government 
policy or maximising health outcomes.
The National Health and Medical Research Council has 
developed standards for clinical practice guidelines 
that require public comment on all draft guidelines 
so that any issues of bias can be disclosed and 
debated in the open. It also has conflict of interest 
guidelines and recently refused to approve a guideline 
developed by an external body (funded by taxpayers’ 
money) because of a conflict that was not dealt with 
by the developers. It is not always possible for those 
people developing guidelines to recognise where 
the perceived or real conflicts exist. It is unclear how 
many connections with industry are too many – what 
is the right number or financial limit?
Creating a framework
A framework for managing conflicts is required 
because it is not always clear when a conflict exists. 
There must be a formalised process in place that 
everyone knows, understands and respects. This 
process needs to be apparent to the people on 
guideline teams, the groups and agencies funding, 
approving and endorsing the guidelines (e.g. 
professional societies, non-government agencies 
and government agencies such as the Department 
of Health and Ageing and the National Health and 
To gain trust in the process, the conflicts need to 
be declared, managed, recorded and made publicly 
available. The Chair of the committee should be free 
from competing interests.
How to decide whether the disclosure 
is a conflict
A nuanced approach to identifying issues and 
influences that may present (or appear to present) a 
conflict is useful. There also needs to be consideration 
of whether a disclosure represents (or is perceived to 
represent) a high- or low-level conflict or influence, 
and appropriate responses are required. Or perhaps 
the views simply represent a valuable perspective? 
It will be important to ascertain whether the view or 
belief carries with it a real or perceived obligation to 
an external party.
Guidelines seek to be as reliable and credible as 
possible. One of the guiding principles in assessing 
the perception of conflict that can be used is to 
ask the question ‘What would be the impact if this 
issue was reported on the front page of a major 
newspaper?’ The answer to the question will help to 
judge the most appropriate ways to understand and 
deal with the declared interest.
The World Health Organization uses evidence juries 
and evidence hearings for managing conflicts of 
interest when the input of commercial groups or 
heavily sponsored groups is required.
Agencies like the Pharmaceutical Benefits Advisory 
Committee and Therapeutic Guidelines need to be 
seen to have high standards of disinterestedness 
because of their public roles and tasks. They provide 
advice on issues in the health sector that have the 
capacity to influence diagnosis, treatment, health 
outcomes and quality of life. They have an enormous 
amount of public credibility and integrity, and their 
reputations are at stake if they don't manage  
interests well.
Recruiting people onto guideline 
development groups
It is important to make every effort to find people  
with expertise who do not have significant ties with  
industry, academic conflicts or personal interests.  
The Pharmaceutical Benefits Advisory Committee  
requires members to make annual declarations of  
interests as well as a meeting-by-meeting declaration  
of interest that is recorded in the minutes. However,  
these declarations are not publicly disclosed, and in  
some cases it might be inappropriate if they were  
(e.g. a member of the committee declaring that a child 
in their family uses a drug that is being considered by 
the committee). Strategies such as recusal or removal 
from the room for the discussion of the item are used 
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background and affiliations before inviting them to 
participate on a guideline development group.
The overall framework of each guideline should 
be considered. The bigger issue beyond conflict 
of interest is whether the scope of the guideline is 
appropriate. For example, will the guideline cover a 
wide range of topics from diagnosis, to treatment, 
use of drugs and rehabilitation? It is also important 
to consider whether the process for considering 
the evidence encourages debate and provides 
opportunity for public consultation and comment. 
Guideline developers should also have a process to 
ensure regular updates of the guidelines so that they 
are relevant and provide advice on the latest most 
reliable evidence.
Medical Research Council), and the users of the 
guidelines (e.g. health practitioners, healthcare 
students and health consumers). Thresholds should 
be agreed in advance so that it is clear how many 
connections with industry are too many. However, 
there are no absolute rules and some conflicts are 
hard to recognise, so there should be a process for 
reviewing declared conflicts as the work of the group 
progresses.
Declarations of conflicts are necessary but not 
sufficient. The time at which disclosures are made 
is also important. To make sure the conflicts can 
be managed and that the appropriate people are 
selected for guideline teams, disclosures should be 
made before inviting people to be involved. Agencies 
like Therapeutic Guidelines need to know the person’s 
PANEL DISCUSSION
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Professor Robert Moulds
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Group discussions
How should the evidence be 
interpreted?
Guideline development teams need to be seen to be 
independent and have a Chair without any conflicts of 
interest and, if required, an expert Co-chair. To ensure 
that guideline teams adopt processes for interpreting 
evidence in a way that addresses the risk of bias, the 
following strategies are proposed:
 • provide training on a standard methodology for 
conducting systematic searches of databases to 
find the most relevant and appropriate data
 • provide training on reporting on critical appraisal 
of the evidence (e.g. detecting bias, interpreting 
the trial results and reporting risk and benefit data)
 • ensure that teams include the right mix of people 
appraising the studies. Evidence should be 
reviewed by multidisciplinary teams.
 • introduce standards for guideline development 
processes, such as recording sources of funding 
for guideline development teams, ensuring that 
guidelines are peer reviewed and open for public 
consultation
 • ensure that there is a balance of the kind of 
evidence that is used in the development of 
guidelines (e.g. looking at issues from different 
perspectives such as remote rural issues and also 
qualitative data)
 • acknowledge where there are areas of 
disagreements between guideline team members 
in the published guidelines.
How should the interests that 
influence decision making be 
described and interpreted?
It is important that people involved in guideline 
development and the assessment of therapeutic 
evidence have appropriate skills and expertise in their 
work. However, there should be a range or balance 
and diversity of interests represented – they should 
not be dominated by one group or one approach.
Before inviting people to join a guideline team, find 
out about each prospective team member's interests.
Discuss the need for transparency of interests with 
the people invited to be part of a guideline or project 
team. Advise them that their declarations of interests 
will be shared with other members of the group and 
published with the guideline.
The forum participants were asked to spend time in 
small groups to discuss the issues raised during the 
day and make suggestions, particularly in relation to 
the following six key questions.
How should the quality of the 
evidence be improved?
It is important to make it very clear from the start 
of any guideline project that there are processes 
and tools that can be used to assess the quality of 
evidence and risk of bias. There should be training 
for the health workforce (providers and researchers) 
to help them understand how to use these tools. 
Ethics committees and guideline development team 
members could be trained on ethical and scientific 
assessment of study design.
A range of changes to the way clinical trials are 
designed and funded are supported, including:
 • increasing the scientific appraisal of research 
projects before submitting proposals to ethics 
committees. This ensures robust design to 
determine the therapeutic benefit of drugs and 
any superiority to existing products
 • encouraging researchers to involve real people in 
trials so that the applicability of the drugs to the 
appropriate populations is rigorously tested
 • requiring researchers to provide full access to all 
trial data in a way that it can be easily and publicly 
accessed
 • promoting the independent funding of research 
rather than relying on industry-funded research, 
such as through the introduction by government 
of a prescriptive 5% tax on the pharmaceutical 
industry to cover the funding of independent 
clinical research
 • increasing the transparency of all clinical trial 
data and making this information freely available. 
For example, research funders/purchasers 
should require registration of trials and access 
to all trial data if industry seeks to have public 
reimbursement of its products
 • providing feedback on the usefulness of the 
research undertaken so that the funders of 
Australian research can commission the research 
that is needed.
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Should the role of guideline 
developers be extended?
Should guideline developers such as Therapeutic 
Guidelines and other guideline development agencies 
include being agents for change? Should they take on 
an ‘activist’ role, promoting change in practice and 
addressing public health outcomes in guidelines?
Some of the activities guideline developers could 
consider include:
 • advocating for greater access to clinical trial 
results
 • identifying and prioritising areas of unmet patient 
need that require more research
 • advocating for increased public funding for clinical 
trials
 • developing strategies to help people understand 
how to use guidelines
 • taking on a broader role with consumer 
information (e.g. promoting evidence-based 
consumer information resources to accompany 
guidelines)
 • broadening the scope of guidelines to include 
diagnosis and social determinants of health. 
Guideline developers could actively consider 
a wider range of interventions (beyond drug 
therapy) for inclusion in guidelines and also 
address deprescribing issues.
 • including discussion about the effectiveness 
of complementary and alternative therapies in 
guidelines and having an agreed process for 
assessing the evidence/effectiveness of these 
therapies
 • extending the remit of guidelines to include 
implementation activities.
There should be full public disclosure of all pecuniary 
and non-pecuniary interests of the group members 
so that the interests can be actively managed by the 
Chair.
Provide the Chairs of guideline development groups 
with training on the range of strategies available to 
manage conflicts of interest.
How should declared interests be 
managed?
There needs to be a clear policy describing the steps 
that can be adopted to manage conflicts, and the 
process for making decisions should be agreed in 
advance. These processes should be reported in 
guidelines or other publications.
Processes for managing conflicts should include:
 • being clear that full disclosure is a requirement of 
participation
 • recording points of difference or disagreement
 • recording how declared interests were managed 
during meetings
 • ensuring that the process includes a way to keep 
sensitive or personal interests private and shared 
only with the Chair.
How do end users interpret 
disclosures of interest?
Clinicians and consumers want to rely on the 
credibility of the agency providing advice. There 
needs to be clear information explaining that 
disclosure of interests is not ‘naming and blaming’, 
but is a credible professional and ethical operating 
process.
End users want to be able to assess the significance 
of the interest, to know that a process of managing 
the interest has been followed, and to be given advice 
about how to interpret the impact of the interest.
It would be useful to research what effect disclosures 
have on the perception of reliability of guidelines.
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RECOMMENDATIONS
Recommendations
Reform of regulatory requirements 
relating to new drugs
 • Approval of new drugs should be subject to the 
criterion of ‘added value’, in addition to present 
requirements for proof of quality, effectiveness 
and safety, to ensure a therapeutic advantage over 
drugs already on the market.
 • It should be a requirement that at least one of the 
two pivotal phase III randomised controlled trials 
should be carried out by an independent not-for-
profit organisation.
 • Pharmacological, toxicological and clinical trial 
data (appropriately de-identified) should be made 
freely available for scrutiny, preferably through 
publicly accessible trial registration websites.
 • Regulatory authorities should be fully funded from 
public sources, independently of the industry they 
are meant to regulate.
Public funding of clinical trials
 • Trials to answer important clinical questions 
without potential commercial benefit should be 
publicly funded. Such research would include trials 
to assess drug safety and effectiveness compared 
to existing best therapy, drug therapy in children 
and the elderly, non-drug therapies and orphan 
drugs used for rare and neglected diseases.
 • Public funding for research could be largely 
derived from a levy on drug companies (e.g. a 
percentage of their marketing budget).
 • All drug trial protocols and results should be 
publicly available to regulators, researchers, 
guideline developers and the public.
 • Areas of unmet patient need should be identified 
and should receive priority public funding.
During the presentations and the discussions 
following them many ideas and strategies were 
proposed to reduce the impact of bias and competing 
interests in guidelines and to improve the quality and 
reliability of the evidence base.
Strategies to manage interests
 • Organisations and working groups involved in the 
development of guidelines and other resources 
should establish clearly defined and transparent 
processes for declaring and managing dualities 
and conflicts of interests.
 • All researchers, academics, committees and 
people involved in such development should be 
required to make declarations of their dualities of 
interests, both pecuniary and non-pecuniary, and 
to give consideration to the potential influence 
of these dualities on the emerging products. This 
should occur at the outset of the development 
process and it should be revisited at every 
meeting.
 • Where possible, the number of participants and 
authors with dualities or conflicts should be 
limited.
 • Published materials should include rigorous 
documentation both of the process for managing 
dualities and conflicts and of the actual interests 
of participants, sufficient to demonstrate how the 
independence and integrity of the final guideline 
or resource was safeguarded. This may entail 
detailed annotations in relation to each part of the 
discussion explaining any relevant issues relating 
to interests and how they were managed.
Improvement of critical appraisal 
skills
 • Researchers, ethics committees, clinicians, 
consumers, and newspaper and media journalists 
should undergo training in techniques for critically 
appraising clinical trial information.
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Appendix 1
Speaker profiles
Professor Silvio Garattini
Silvio Garattini qualified 
in medicine in 1954. He 
was appointed as lecturer 
in chemotherapy and 
pharmacology.
He was the founder of the 
Mario Negri Institute for 
Pharmacological Research and 
was its director when it opened in 1961. The Institute 
now has a staff of more than 850 people in three 
locations and in its 50 years has published more 
than 12 000 scientific papers and more than 250 
books, on topics such as cancer and its treatment, 
tumour immunology, neuropsychopharmacology, and 
cardiovascular and renal pharmacology.
Professor Garattini was a member of Commissione 
Unica del Farmaco (the Italian organisation that 
decides on the reimbursement of drugs) from 1993  
to 1997, member of Committee for Medicinal  
Products for Human Use (European Medicines 
Agency) from 1997 to 2004, Chairman of the 
Committee for Clinical Research (Agenzia Italiana 
del Farmaco) from 2005 to 2010, and is currently a 
member of the National Committee on Bioethics. He 
was also a founder of the European Organisation for 
Research and Treatment of Cancer. He has received 
many awards for his work, including the French 
Legion d’Honneur for Scientific Merit, and the Grande 
Ufficiale della Repubblica Italiana, the Medaglia d’Oro 
al Merito della Sanità Pubblica granted by the Italian 
Ministry of Health.
Mr Richard Kneebone
Richard Kneebone is the 
Chairman of the Board of 
Directors of Therapeutic 
Guidelines Limited. He is a 
qualified lawyer and consultant 
on corporate governance and 
compliance and was formerly 
employed as Company 
Secretary for Orica Ltd, Company Secretary for 
BHP Billiton and subsidiaries, General Counsel and 
Company Secretary for Australian National Line, and 
Legal Advisor for Hong Kong Mass Transit Railway 
Corporation. Before that he was in private practice.
Dr Sue Phillips
Sue Phillips is the Chief 
Executive Officer of 
Therapeutic Guidelines Limited. 
She was awarded a Doctorate 
of Philosophy by the University 
of Oxford in 1985 for her 
research on cellular immune 
responses to developmental 
tumours. She was formerly employed as Director 
and Interim Executive Director at the National Health 
and Medical Research Council’s National Institute 
of Clinical Studies, Senior Policy Analyst at the 
Royal Australian College of General Practitioners, 
Director in various health policy positions within the 
Australian Government’s Department of Health and 
Ageing, and Post Doctoral Research Fellow at the 
Australian National University John Curtin School 
of Medicine and Monash University Biochemistry 
Department. In 2008, Sue was awarded an Australia 
Day Achievement Medallion for services that have 
made a significant contribution to the nation. Sue is 
a member of the Guidelines International Network 
Board of Trustees.
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Associate Professor Ian Kerridge
Ian Kerridge is Director and 
Associate Professor in Bioethics 
at the Centre for Values, Ethics 
and the Law in Medicine at 
the University of Sydney, and 
Staff Haematologist/Bone 
Marrow Transplant physician 
at Royal North Shore Hospital, 
Sydney. He is the author of over 150 papers in peer-
reviewed journals and five textbooks of ethics, most 
recently Ethics and Law for the Health Professions 
(Federation Press). He is a member of the Australian 
Health Ethics Committee, Chair of the Australian Bone 
Marrow Donor Registry Research Committee, and 
a member of the NSW Health Department’s Clinical 
Ethics Advisory Panel. His current research interests 
in ethics include public health ethics, the philosophy 
of medicine, stem cells, prescription drug policy, end-
of-life care, synthetic biology, and organ donation and 
transplantation.
Assistant Professor Barbara Mintzes
Barbara Mintzes is an Assistant 
Professor with the School 
of Population and Public 
Health at the University of 
British Columbia. The main 
focus of her research is 
on pharmaceutical policy, 
including the effects of 
direct-to-consumer advertising and physician-
directed promotion on prescribing and medicine use 
decisions. She also carries out systematic reviews of 
the effectiveness and safety of new drugs with the 
university’s Therapeutics Initiative. These reviews 
are used as background information for provincial 
reimbursement decisions. Dr Mintzes has a PhD in 
Health Care and Epidemiology from the University 
of British Columbia, and holds a Michael Smith 
Foundation for Health Research Scholar Award.
Professor Paul Komesaroff
Paul Komesaroff is a physician, 
medical researcher and 
philosopher at Monash 
University in Melbourne, where 
he is Professor of Medicine and 
Director of the Centre for Ethics 
in Medicine and Society.
He is a practising clinician, 
specialising in the field of endocrinology; his scientific 
research work focuses on the effects of hormones 
on the cardiovascular system and the development 
of noninvasive techniques for assessment of 
cardiovascular risk.
Paul is the Director of the Clinical Ethics Service at 
the Alfred Hospital, Ethics Convener of the Royal 
Australasian College of Physicians and Chair of the 
Royal Australasian College of Physicians Expert 
Advisory Group on Ethics, Executive Director of 
Global Reconciliation and Chair of the International 
Health Workforce Society of Australasia.
Paul has been actively involved in numerous 
committees, including the Victorian Justice Health 
Advisory Committee, the Victorian Department 
of Human Service Genetics Advisory Committee, 
Australians Donate, the ethics committees of the US 
Endocrine Society and Australian Medical Association, 
and the Australasian Bioethics Association.
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Speaker disclosures
Paul Komesaroff made the following disclosures:
 • Clinician and researcher
 • Professor of Medicine, Monash University
 • Director of Centre for Ethics
 • Engaged in research into menopause and the 
cardiovascular effects of steroid hormones
 • Collaborative relationships in research projects, 
past and present, with pharmaceutical companies
 • Ethics convener of the Royal Australasian College 
of Physicians 
 • Principal author of Royal Australasian College 
of Physicians ‘Guidance for Ethical Relationships 
Between the Medical Profession and Industry’ and 
other documents
 • Member or Chair of various ethics committees
 • Executive Director, Global Reconciliation
Ian Kerridge made the following disclosures:
 • Not employed (or reimbursed) by the 
pharmaceutical industry
 • Not a member of advisory group or engaged as a 
consultant for the pharmaceutical industry
 • Receives no travel or academic support from the 
pharmaceutical industry
 • Not a shareholder of any pharmaceutical industry
 • Contributes to enrolling patients into clinical trials 
sponsored by Roche, Pfizer, Cellgene, CSL, Onyx 
and Amgen
 • Chair of HPC Transplant Group and member of 
Haematology Group for NSW Cancer Institute
 • Member of Royal Australasian College of 
Physicians Ethics Committee and the Australian 
Health Ethics Committee 
Sue Phillips made the following disclosure:
 • Guidelines International Network board member 
and contributing author to the paper she quoted in 
her presentation: 
Qaseem A, Forland F, Macbeth F, Ollenschlager G, 
Phillips S, van der Wees P. Guidelines International 
Network: toward international standards for 
clinical practice guidelines. Ann Intern Med 
2012;156:525-31.
Silvio Garattini explained the Mario Negri Policy on 
Independence, which includes:
 • Independence from politics, industry, finance and 
ideology or religion
 • The Institute has many funding streams with no 
more than 10% of the total budget from a single 
source
 • No patent applications
 • Allow collaboration with industry but require 
ownership of data until publication
 • Insist on freedom of expression in all publications.
Barbara Mintzes made the following disclosures:
 • No conflicts of interest to declare
 • Associated with the Therapeutics Initiative, which 
hosts the Cochrane Hypertension review group
 • Publicly funded (Canadian Institutes of Health 
Research, Michael Smith Health Research 
Foundation, British Columbia Ministry of Health)
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Participants
Name Role Organisation Location
Ms Jo Allardice Editor Therapeutic Guidelines Limited Melbourne
Professor Chris 
Baggoley
Chief Medical Officer Department of Health and Ageing Canberra
Mr Martin Basedow Lecturer, Health Care 
Management
Flinders University Adelaide
Dr Margaret Beavis General practitioner Melbourne
Dr Phil Bergen Lecturer Centre for Medicine Use and Safety, 
Monash University
Melbourne
Ms Marion Berry Manager, Melbourne Office NHMRC Melbourne
Ms Alice Bhasale Consumer Team Leader NPS MedicineWise Sydney
Professor Frank 
Bowden
Principal Medical Advisor ACT Health Directorate Canberra
Professor Jo-anne 
Brien
Professor of Clinical 
Pharmacy
St Vincent’s Hospital,  
University of Sydney
Sydney
Ms Siobhan Brophy Communications Manager National Asthma Council Australia
Dr Heather Buchan Director, Implementation 
Support
Australian Commission on Safety 
and Quality in Health Care
Sydney
Professor Rachelle 
Buchbinder
Director 
Professor and NHMRC 
Practitioner Fellow 
Joint Coordinating Editor 
Monash Department of Clinical 
Epidemiology, Cabrini Hospital 
Department of Epidemiology 
and Preventive Medicine, Monash 
University
Cochrane Musculoskeletal Group
Melbourne
Ms Nicki Burridge Publications Pharmacist Society of Hospital Pharmacists of 
Australia
Melbourne
Professor Terry 
Campbell
Senior Associate Dean Faculty of Medicine, University of 
New South Wales
Sydney
Dr Shane Carney Physician John Hunter Hospital Newcastle, 
New South 
Wales
Professor John Condon Professor of Psychiatry Flinders University, Daw Park 
Repatriation Hospital
Adelaide
Mr Glen Cormick Manager, Business 
Development
Baker IDI Heart and Diabetes 
Institute
Melbourne
Ms Karen Crawford Health Professional Training 
Coordinator
Diabetes Australia
Dr Marilyn Cruickshank Healthcare Associated 
Infection Program Manager
Australian Commission on Safety 
and Quality in Health Care
Sydney
Dr Sladjana Cvetkovic Medicines Information 
Manager
NPS MedicineWise Sydney
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Dr Jonathan Dartnell Executive Manager, 
Innovation and Learning
NPS MedicineWise Melbourne
Ms Susan Daskalakis Editor Therapeutic Guidelines Limited Melbourne
Dr Janice Davies Consultant Whole Systems Work Melbourne
Ms Janette Donovan Consumer representative Melbourne
Dr John Dowden Medical Editor Australian Prescriber Canberra
Mr Geraint Duggan Assistant Director, 
Guidelines Program
National Health and Medical 
Research Council
Melbourne
Ms Leia Earnshaw Acting Assistant Director National Blood Authority
Mr Peter Francis Lawyer Maddocks Melbourne
Professor Silvio 
Garattini
Director Mario Negri Institute for 
Pharmacological Research
Milan, Italy
Professor Alastair Goss Professor, Oral and 
Maxillofacial Surgery 
University of Adelaide Adelaide
Professor Lindsay 
Grayson
Professor/Director, 
Infectious Diseases
Austin Health and University of 
Melbourne
Melbourne
Dr Peter Greenberg Physician Department of General Medicine, 
Royal Melbourne Hospital
Melbourne
Dr Robert Grenfell National Director, 
Cardiovascular Health
Heart Foundation Melbourne
Mr Stephan 
Groombridge
Program Manager Royal Australian College of General 
Practitioners
Melbourne
Ms Natalie Hannaford Research Fellow University of South Australia Adelaide
Dr Ken Harvey Melbourne
Dr James Hayes Emergency Physician Northern Hospital Melbourne
Ms Mary Hemming Consultant Therapeutic Guidelines Limited Melbourne
Mr Kelvin Hill National Program Manager, 
Clinical Issues
National Stroke Foundation Sydney
Dr Suzanne Hill Chair, Pharmaceutical 
Benefits Advisory 
Committee
Department of Health and Ageing Canberra
Dr Ingrid Hopper Clinical Pharmacologist Alfred Hospital Melbourne
Ms Susan Huckson Manager, Centre for 
Outcome and Research 
Evaluation
Australian and New Zealand 
Intensive Care Society
Melbourne
Professor Alan 
Husband
Health Professional 
Team Leader, Medicines 
Information
NPS MedicineWise Sydney
Professor Garry 
Jennings
Director Baker IDI Heart and Diabetes 
Institute
Melbourne
Ms Melanie 
Jeyasingham
Editor Therapeutic Guidelines Limited Melbourne
Dr Jane Johnson Research Fellow, 
Department of Philosophy
Macquarie University Sydney
Mrs Jenny Johnstone Editorial Director Therapeutic Guidelines Limited Melbourne
Dr Sarina Kempe Clinical Pharmacology 
Registrar
Alfred Hospital Melbourne
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Associate Professor Ian 
Kerridge
Director Centre for Values, Ethics and the 
Law in Medicine, University of 
Sydney
Sydney
Ms Benafsha Khariwala Editor Therapeutic Guidelines Limited Melbourne
Miss Carol-Anne 
Kilkenny
Medical Writer NPS MedicineWise Sydney
Ms Georgina Kilroy Editor Therapeutic Guidelines Limited Melbourne
Mr Richard Kneebone Chair, Board of Directors Therapeutic Guidelines Limited Melbourne
Professor Paul 
Komesaroff
Director Monash Centre for the Study of 
Ethics in Medicine and Society
Melbourne
Ms Catherine Lavars Assistant Director, Clinical 
Adviser
Department of Health and Ageing Canberra
Ms Kerry Lavery Project Officer Australian and New Zealand 
Intensive Care Society
Melbourne
Ms Rebecca Lee Project Officer Heart Foundation Melbourne
Ms Anne Leversha Senior Lecturer Monash University Melbourne
Ms Emma Lourey Senior Program Officer, 
Health Professional Learning
NPS MedicineWise Melbourne
Dr Liz Marles President Royal Australian College of General 
Practitioners
Sydney
Ms Catherine Marshall Independent Guideline Adviser  
and Health Consultant 
New Zealand
Professor Christine 
McDonald
Director Department of Respiratory and 
Sleep Medicine, Austin Hospital
Melbourne
Dr Aidan McElduff Endocrinologist Northern Sydney Endocrine Centre Sydney
Ms Angela Melder Clinical Effectiveness Senior 
Consultant and Manager
Quality Unit, Monash Medical 
Centre
Melbourne
Associate Professor 
David Menkes
Associate Professor of 
Psychiatry
University of Auckland New Zealand
Assistant Professor  
Barbara Mintzes
Assistant Professor School of Population and Public 
Health, University of British 
Columbia
Vancouver, 
Canada
Ms Deborah Monk Director, Innovation and 
Industry Policy
Medicines Australia Canberra
Ms Georgia Morris Senior Policy Advisor Australian Medical Association Sydney
Professor Rob Moulds Medical Advisor Therapeutic Guidelines Limited Melbourne
Ms Carol Norquay Electronic Production Editor Therapeutic Guidelines Limited Melbourne
Mr Mark Olszewski Communications Project 
Officer
National Asthma Council Australia Melbourne
Ms Ali Patterson Publishing Director Therapeutic Guidelines Limited Melbourne
Associate Professor 
Christopher Pearce
Clinical Design Lead National E-Health Transition 
Authority
Sydney
Dr Sue Phillips Chief Executive Officer Therapeutic Guidelines Limited Melbourne
Dr Jane Robertson Senior Lecturer, Clinical 
Pharmacology
University of Newcastle Newcastle, 
New South 
Wales
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Dr Susie Rogers Editor Therapeutic Guidelines Limited Melbourne
Dr Philipa Rothfield Senior Lecturer, Philosophy 
Program
La Trobe University Melbourne
Ms Sandy Scholes Pharmacist Melbourne
Dr Ian Scott Director Internal Medicine and Clinical 
Epidemiology, Princess Alexandra 
Hospital
Brisbane
Ms Vanessa Simpson Medical Writer NPS MedicineWise Sydney
Ms Lishia Singh Coordinator, Business 
Development
Baker IDI Heart and Diabetes 
Institute
Melbourne
Associate Professor 
Jane Smith
Associate Professor of 
General Practice
Bond University Medical School Gold Coast, 
Queensland
Dr Kay Sorimachi Director, Policy and 
Regulatory Affairs
Pharmaceutical Society of Australia Melbourne
Ms Janet Struber Coordinating Editor Centre for Remote Health Alice Springs, 
Northern 
Territory
Professor Martin 
Tattersall
Professor of Cancer 
Medicine
Department of Medicine, Central 
Clinical School, University of 
Sydney
Sydney
Professor John Tiller Director Therapeutic Guidelines Limited Melbourne
Dr Janet Wale Consumer representative Melbourne
Dr Judith Walker Senior Policy Officer, Policy 
and Advocacy Unit
The Royal Australasian College of 
Physicians
Sydney
Dr John Waterston Consultant Neurologist Alfred Hospital and Cabrini Medical 
Centre
Melbourne
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Further reading
The following list of background references was provided to Independence Forum participants.
Independence: what’s the point? ISDB General 
Assembly. Melbourne; 14 September 2005.  
www.isdbweb.org/documents/uploads/
Independence_000.pdf [cited 2013 Aug 12]
Avraham R. Clinical practice guidelines: the warped 
incentives in the U.S. healthcare system.  
Am J Law Med 2011;37:7-40. 
Boyd EA, Bero LA. Improving the use of research 
evidence in guideline development: 4. Managing 
conflicts of interests. Health Res Policy Syst  
2006;4:16. 
Gale EA. Between two cultures: the expert 
clinician and the pharmaceutical industry. Clin Med 
2003;3:538-41. 
Gale EA. Conflicts of interest in guideline panel 
members. BMJ 2011;343:d5728. 
Guyatt G, Akl EA, Hirsh J, Kearon C, Crowther M, 
Gutterman D, et al. The vexing problem of guidelines 
and conflict of interest: a potential solution.  
Ann Intern Med 2010;152:738-41. 
Hirsh J, Guyatt G. Clinical experts or methodologists 
to write clinical guidelines? Lancet 2009;374:273-5. 
Ioannidis JPA. Why most published research findings 
are false. PLoS Med 2005;2:e124. 
Johnson AJ, Rogers WA. Conflict of interest 
guidelines for clinical guidelines. Med J Aust 
2012;196:244-5. 
Mintzes B. New UK guidance on industry-health 
professional collaboration. BMJ 2012;344:e3952. 
Norris SL, Holmer HK, Ogden LA, Burda BU. Conflict 
of interest in clinical practice guideline development: 
a systematic review. PLoS One 2011;6:e25153. 
Robertson J, Moynihan R, Walkom E, Bero L, Henry D.  
Mandatory disclosure of pharmaceutical industry-
funded events for health professionals. PLoS Med 
2009;6:e1000128. 
Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, 
Thombs BD. Reporting of conflicts of interest from 
drug trials in Cochrane reviews: cross sectional study. 
BMJ 2012;345:e5155. 
Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, 
Turner EH, et al. Reporting of conflicts of interest in 
meta-analyses of trials of pharmacological treatments. 
JAMA 2011;305:1008-17. 
Williams MJ, Kevat DAS, Loff B. Conflict of interest 
guidelines for clinical guidelines. Med J Aust 
2011;195:442-5. 
Zuiderent-Jerak T, Forland F, Macbeth F. Guidelines 
should reflect all knowledge, not just clinical trials. 
BMJ 2012;345:e6702. 
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